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CHAPTER I 
 
INTRODUCTION 
 
Helicobacter pylori     
Helicobacter pylori  is a microaerophilic, spiral-shaped, Gram-negative bacterium 
that colonizes the human stomach (25, 87, 104).  H. pylori resides primarily within the 
gastric mucus layer, but it can also adhere to gastric epithelial cells (5, 26, 82).  More 
than 50% of the human population is thought to be infected with H. pylori (25, 87, 104).  
Once infection is established, H. pylori has no significant bacterial competitors and it can 
persist for decades in the absence of antimicrobial treatment.  Infection with this 
bacterium induces extensive inflammation of the gastric mucosa (i.e. gastritis) and is 
considered to be a major risk factor for the development of peptic ulcer disease, gastric 
adenocarcinoma, and gastric lymphomas (25, 72, 87, 104).  Gastric adenocarcinoma is 
the second leading cause of cancer-related deaths in the world, and has been associated 
with the presence of H.  pylori in the stomach (72).  Only a small percentage 
(approximately 3%) of individuals infected with H. pylori ever develop cancer or peptic 
ulcers, indicating that other factors are involved (i.e. environmental, diet, and host 
factors) (72).  H. pylori infection can be eradicated by treatment with antibiotics, but 
most antibiotic treatment regimens require the use of multiple drugs for at least a week.  
Experiments involving animal models indicate that it may be possible to develop an H. 
pylori vaccine that confers protective immunity (10, 78), but thus far there is no H. pylori 
vaccine commercially available for use in humans.  
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Helicobacter pylori virulence factors 
H. pylori has evolved sophisticated mechanisms that allow its survival and growth 
in the hostile environment of the human stomach.  Two independent H. pylori strains 
have been sequenced and the overall genomic organization and predicted proteomes of 
the two strains are fairly similar (4).  However, about 6-7% of the genes identified are 
present in one of the strains but not the other (4, 91).  H. pylori populations have been 
shown to be highly diverse (39).  For example, a single host can carry many closely 
related H. pylori strains that are derived from one parental strain by a series of mutations, 
chromosomal rearrangements, and recombinational events (39).  Even though H. pylori 
diversity has made it somewhat difficult to search for bacterial factors that are associated 
with disease, within the past twenty years a variety of virulence factors have been 
described.  H. pylori expresses flagella and urease, which are thought to be two of the 
most important factors for H. pylori colonization and survival in the human stomach (11).  
Flagella presumably allow the bacteria to enter and move within the gastric mucus layer 
(65), and urease hydrolyzes down urea into ammonia, which contributes to the acid 
resistance of H. pylori (55).  In addition, most H. pylori strains express a variety of 
adhesins, as well as porins, catalase, and other virulence determinants.  
Two of the most extensively studied H. pylori virulence factors are the cag 
pathogenicity island (PAI) (13) and the vacuolating cytotoxin (VacA) (43).  The PAI 
encodes a type IV secretion apparatus that is used to translocate the H. pylori effector 
protein CagA (63, 86), as well as bacterial peptidoglycan into the eukaryotic cell (99).  
Inside mammalian cells, CagA localizes to the cell membrane and is phosphorylated by 
members of the Src family of tyrosine kinases (85).  Phosphorylation of CagA has been 
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associated with the activation of the host-cell tyrosine phosphatase SRC homology 2-
phosphatase (SHP-2), resulting in aberrant host-cell signaling and morphological changes 
characterized by extensive rearrangement of the actin cytoskeleton (6, 36).  H. pylori 
peptidoglycan translocated into host cells has been shown to be recognized via Nod1 
(99), an intracellular pathogen-recognition molecule specific for Gram-negative 
peptidoglycan (35).  Activation of Nod1 by H. pylori results in the activation of a 
proinflammatory response in gastric epithelial cells (99).  Another important H. pylori 
virulence factor, the vacuolating cytotoxin (VacA) (43), is the focus of this thesis work 
and will be described in more detail in the sections below.   
 
Helicobacter pylori vacuolating cytotoxin (VacA) 
In 1988 Leunk et al reported that broth-culture supernatants from H. pylori 
isolates contained a proteinaceous cytotoxin that was able to induce cytoplasmic 
vacuolation in eukaryotic cells (Fig. 1) (43).  Subsequently, a protein with vacuolating 
activity named VacA was purified from H. pylori broth-culture supernatants (15).  All 
clinical H. pylori isolates contain the vacA gene, but not all isolates express a cytotoxic 
VacA protein (approximately 50% of strains from the U.S. patients produce detectable 
vacuolating cytotoxic activity in a HeLa cell assay) (7, 8, 15).  Variation in levels of 
cytotoxicity produced by different strains has been related to vacA allelic variation among 
H. pylori isolates (Fig. 2) (7).  Two different types of VacA signal sequences (s1 and s2) 
and two types of VacA mid-regions (m1 and m2) have been described (7).  Mosaic forms 
of vacA are thought to arise via homologous recombination among different vacA alleles.   
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Figure 1.   Cytotoxic effects of VacA on HeLa cells.  HeLa cells 
were treated as described below, for 2 h at 37 °C, stained with crystal 
violet (A and B) or with Neutral Red, and then visualized by microscopy. 
A) Cells treated with buffer without VacA. B and C), Cells intoxicated 
with acid-activated VacA (5 µg/ml). 
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H. pylori isolates containing an s1-m1 vacA allele are the most toxic strains 
followed by H. pylori strains containing s1-m2 vacA alleles (7).  The H. pylori isolates 
containing s2-m1 or s2-m2 vacA alleles do not exhibit detectable cytotoxic activity in 
vitro, and are infrequently associated with symptomatic disease(7).  
 
Expression, regulation, and secretion of the mature VacA protein 
Very little is known about how H. pylori regulates expression of the VacA 
protein.  It has been shown that VacA expression is upregulated after initial contact of H. 
pylori with human gastric epithelial cells in vitro (98).  Moreover, VacA expression has 
been shown to be induced under acidic conditions and in response to iron starvation (9, 
54).   
The vacA gene encodes a precursor 139-140 kDa protoxin (15, 18, 80, 90).  The 
139-140 kDa protoxin undergoes cleavage of an N-terminal signal sequence and cleavage 
of a C-terminal auto-transporter domain to produce a final secreted product of 88 kDa 
(Fig. 2) (61).  The signal sequence facilitates the transport of the protoxin from the 
cytoplasm to the periplasm.  Once in the periplasm, it is believed that the toxin is 
translocated to the outer membrane using its auto-transporter domain.  VacA can remain 
associated with the surface of the bacteria, from which can be transferred directly to host 
cells at the bacteria-cell interface, or it can be secreted into the extracellular environment 
as a soluble protein (38).  Analyses of the amino acid sequence of the mature secreted 
VacA have shown no striking similarity to any known bacterial toxin or protein.   
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Figure 2.  Schematic representation of VacA protein.  The H. pylori vacA 
gene is translated as a 139-140 kDa protoxin and shows no striking similarity to any 
known bacterial toxin.  Upon expression, this protoxin undergoes amino- and 
carboxyl-terminal processing to yield a mature 88-kDa secreted VacA toxin.  The 
mature VacA toxin can be cleaved into amino- and carboxyl-terminal fragments, of 
33-kDa (p33) and 55 kDa (p55), respectively (15, 61, 90).  
Role of VacA in gastroduodenal disease 
 Experimental animal studies and epidemiological studies have suggested that 
VacA is an important virulence factor in H. pylori pathogenesis (7, 30, 90).  Oral 
administration of sonicated extract from H. pylori strains containing s1-m1 VacA to mice 
induces pathological lesions similar to those found in human biopsies (48).  In addition, 
oral administration of purified VacA protein to mice induces gastric ulceration (90).  
VacA also induces cell vacuolation in vivo in the stomach of animal models as well as in 
primary gastric cell cultures (30, 43, 48, 90).  Cell vacuolation has also been observed in 
biopsies of infected humans (90).  The importance of VacA-induced vacuolation in H. 
pylori-mediated diseases remains poorly understood.  It seems likely that additional 
activities of VacA may be important in vivo.   
 
VacA effects on mammalian cells 
The H. pylori VacA toxin produces a wide array of structural and functional 
alterations in intoxicated mammalian cells (Fig. 3).  The most prominent VacA effect is 
the formation of large vacuoles within the cytoplasm of mammalian cells, an effect 
observed about 90 minutes after VacA intoxication (Fig. 1 and 3) (15, 43).  VacA-
induced vacuoles accumulate several cell-permeable dyes, including the acidotrophic dye 
neutral red, which becomes trapped inside the VacA-induced vacuoles (15).  The ability 
of VacA-induced vacuoles to accumulate neutral red provides the basis for a quantitative 
assay (neutral red uptake assay) which is used to assess vacuolating activity of VacA 
proteins (15).  Vacuoles induced by VacA originate from membrane-bound 
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compartments of the late endocytic pathway and are characterized by the presence of V-
ATPase and the small GTP-binding protein rab7 (44, 67, 68). 
Another important activity of VacA is its ability to form membrane channels (19).  
VacA forms hexameric, anion-selective, channels upon insertion into planar lipid 
bilayers, and in cell membranes(Fig. 3) (19, 89).  The formation of VacA channels in the 
plasma membrane of cells results in increased permeability to small anions, including 
chloride, bicarbonate, and pyruvate, with consequent membrane depolarization (69).  
VacA membrane channels have been shown to be responsible for VacA vacuolating 
cytotoxic activity (Fig. 3)(93, 100).  It has been proposed that VacA causes cell 
vacuolation by forming anion-selective channels in the membrane of endocytic 
compartments (Fig. 3)(44).  VacA also increases transepithelial permeability of polarized 
epithelial monolayers to ions, such as iron, and nickel, as well as small sugars and urea 
(Fig. 3) (69, 74, 92).  The ability of VacA to increase the transepithelial permeability of 
these molecules might be beneficial for H. pylori, since iron, nickel, and sugars can be 
used as nutrients, and hydrolysis of urea contributes to the acid resistance of H. pylori. 
VacA seems to have the ability to induce a variety of detrimental effects on host 
cells in vitro (see Fig. 3) (58, 70).  Other VacA effects on mammalian cells include i) 
apoptosis (17), presumably by disrupting the mitochondria membrane potential, resulting 
in cytocrome c release (31, 105, 106);  ii) clustering and redistribution of late endocytic 
compartments (44, 67, 68), which might result in interference with class II antigen 
presentation (56), impairment of endocytic trafficking (79), and disruption of phagosome 
maturation in macrophages (3, 115);  iii) detachment of epithelial cells from the basement 
membrane, an effect dependent on VacA interaction with RPTP-β (see below) (30);  iv) 
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activation of mitogen-activated protein kinase (MAPK) p38 and extracellular signal-
regulated kinase 1/2 (Erk1/2), effects dependent on VacA binding to the cell surface but 
not on VacA channel activity (12, 59, 88); and, v) inhibition of activation-induced 
proliferation of T lymphocytes (this topic will be described in more detail in CHAPTER 
IV) (12, 34).  Many of these effects have been shown to be dependent on the capacity of 
VacA to form anion-selective membrane channels (17, 88, 100, 105, 106).  Potentially 
several of these effects of VacA are relevant to H. pylori pathogenesis in vivo.     
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 Figure 3.  Model of VacA effects on mammalian cells. VacA can be found 
bound to H. pylori surfaces or secreted.  Secreted VacA binds to putative cellular 
receptor(s) inducing the activation of proinflammatory signals.  VacA has been shown to 
activate the mitogen-activated protein kinases (MKK) 3/6, p38, and the extracellular 
signal-regulated kinase (ERK) 1/2 in gastric epithelial cells as well as in immune cells.  
VacA also is internalized into host cells.  Internalized VacA can localize to late 
endosomes or mitochondria.  VacA interactions with mitochondria lead to reduced 
mitochondrial membrane potential and cytochrome c release, resulting in cell death.  
VacA also induces increased paracellular permeability and reduced transepithelial 
electrical resistance in polarized cells.  These effects might allow VacA to migrate from 
the stomach lumen to the lamina propia, were VacA can interact with immune cells.  
VacA can also interact with epithelial cell surfaces to form anion-selective membrane 
channels allowing chloride transport across the cell membrane.  Endocytosed VacA 
causes clustering of late endocytic compartments, and swelling of these clustered 
endosomes results in the formation of VacA-induced vacuoles.  
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VacA receptors and internalization mechanism 
In order for VacA to exhibit cytotoxic effects, it must bind to the plasma 
membrane of cells and then undergo internalization (53).  The process of VacA binding 
to mammalian cells has been studied for several years, but whether there is a specific 
VacA receptor is still controversial.  It is thought that the carboxy-terminal region of 
VacA is responsible for binding to a putative receptor on the epithelial cell surface (32, 
76, 101, 103).  Indeed, several cell-surface receptors for VacA have been reported, 
including two receptor protein tyrosine phosphatases (RPTP α and β) (30, 109), the 
epidermal growth factor receptor (83), and heparan sulfate (97), a glycosaminoglycan 
present on the surface of most eukaryotic cells.  VacA binding to RPTP molecules has 
been studied in the most detail, and has been shown to be dependent on post-translation 
modifications of these receptors, suggesting that VacA might recognize sialic acid and 
sugar moieties on these proteins (109, 110).  Cells resistant to VacA cytotoxic effects 
become sensitive when transfected with RPTP-β expressing-plasmids, suggesting that 
RPTP-β is involved in VacA intoxication (66).  Similarly, VacA-sensitive cells treated 
with RPTP-α or β morpholino antisense oligonucleotide before intoxication are resistant 
to VacA cytotoxicity (66, 109).  Interestingly, in mice that do not express RPTP-β in the 
stomach, VacA still binds to gastric cells and induces vacuolating cytotoxic activity, 
suggesting that VacA can use more that one receptor to exhibit its cytotoxic effects on 
mammalian cells (30).  In addition, VacA localizes to sphingolipid-cholesterol-rich-
membrane microdomains (lipid rafts) on the surface of mammalian cells (81).  It might 
be possible that VacA binds to protein receptors as well as to lipids on the surface of host 
cells.   
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Following binding of VacA to the plasma membrane, the toxin is internalized by 
cells (53), a process inhibited by the disruption of lipid rafts (33, 42, 71, 81), suggesting 
that VacA may use lipid rafts for binding and internalization.  The exact mechanism 
employed by VacA to gain access to the cytoplasm of mammalian cell is largely 
unknown.  It has been proposed that VacA binds to a receptor which undergoes 
endocytosis, allowing the toxin to be internalized via a clathrin-independent pathway (71, 
77).  It might be possible that VacA binds to a cell surface molecule(s), promoting the 
aggregation of VacA in lipid rafts on the cell surface, which in turn, induces VacA 
insertion into the cell membrane and pore-formation, followed by internalization of these 
VacA complexes via an actin-dependent endocytic process. 
 
p33 and p55 VacA domains 
The mature secreted 88 kDa VacA toxin can undergo spontaneous proteolytic 
degradation into fragments that are about 33 and 55 kDa in mass (16, 32, 61, 90). This 
degradation has been observed especially when preparations of the purified toxin are 
stored for prolonged periods (32, 90).  Whether the generation of the 33- and 55 kDa 
VacA fragments is the result of auto-proteolysis is not currently known.  It has been 
presumed that the two fragments (termed p33 and p55) represent two domains or subunits 
of VacA (46, 76, 90).  Several lines of evidence indicate that amino acid sequences 
located within a hydrophobic region near the N-terminus of the p33 domain are required 
for the formation of anion-selective membrane channels (49, 52, 100, 112), and that 
amino acids within the p55 domain are responsible for VacA binding to mammalian cells 
(32, 76, 101, 103).  Interestingly, when transiently expressed within mammalian cells, 
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neither the p33 nor the p55 VacA domain is sufficient for vacuolating cytotoxic activity 
(113).  In contrast, when the p33 and p55 are transiently co-expressed within mammalian 
cells, they complement each other, resulting in vacuolating activity (113).  
 
VacA oligomeric structure 
Over the past decade, several lines of evidence have suggested the occurrence of 
homotypic interactions among 88 kDa VacA proteins (15, 50, 76, 90, 100, 107, 111).  
The first evidence suggesting oligomerization of VacA proteins was the observation that 
purified VacA from H. pylori broth culture supernatant assembles into structures of 
~1,000 kDa in mass under non-denaturing conditions (15).  Ultrastructural studies have 
shown that VacA complexes have a flower-like shape structure and are composed of 
anywhere from 6 to 14 VacA monomers (Fig. 4) (1, 16, 46).  In addition, it has been 
shown that these flower-shaped structures disassemble into VacA monomers after 
exposure to acid or alkaline pH and then reassemble into the flower-shaped structures 
after neutralization (16).  Additional evidence of VacA assembly into oligomeric 
structures has come from experiments in which two different VacA toxins have been 
shown to form mixed oligomeric structures (50, 100).  It is believed that VacA assembly 
into oligomeric structures is required for the toxin’s cytotoxic affects.    
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Figure 4. Flower-like VacA structure.  A) Purified VacA 
molecules imaged by deep-etch electron microscopy.  Rotary replica of a 
purified and freeze-dried VacA flower purified from broth culture 
supernatants of tox+ H. pylori strain 60190 (s1/m1 VacA).  B) A structural 
model of VacA based on the flower view, interpreted to be a duodecamer 
composed of two hexameric flat forms interlocked face-to-face.  Pictures 
were modified from Cover et al (16). 
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Research significance and specific aims 
 
Study of VacA oligomerization
Experimental and epidemiological studies have suggested that the vacuolating 
cytotoxin (VacA) is an important virulence factor in H. pylori pathogenesis, and that 
VacA contributes to the development of stomach and duodenal ulcers (7, 30, 90).  VacA 
assembly into oligomeric structures able to form membrane channels is thought to be 
required for most VacA-induced effects on mammalian cells.  This hypothesis is 
supported by electron microscopy studies in which VacA associated with membranes 
appears as flower-shaped structures (1), as well as electrophysiologic studies in which the 
kinetics of membrane channel formation suggest that the VacA channel is a hexamer 
(40).   
Previous studies have demonstrated that the mature secreted VacA toxin can 
undergo spontaneous proteolytic degradation to yield two fragments (p33 and p55) (16, 
90).   It has been suggested that these two fragments represent two distinct VacA 
functional domains, but in the absence of a VacA crystal structure, the relevant features 
of these two putative domains remain poorly characterized.  The study of the proccess of 
VacA assembly into oligomeric strucutures and the role of p33 and p55 domains in VacA 
assembly has been hindered by the lack of over-expression systems that allow the 
production of functionaly active recombinant VacA proteins.  Furthermore, VacA 
domains involved in toxin binding and internalization into mammalian cells have not yet 
been decribed in any detail.  Thus, the main goal of this thesis was to identify functional 
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domains of VacA, and in particular, to characterize the role of p33 and p55 domains in 
the process of VacA oligomerization and intoxication of mammalian cells.   
Proteins normally exist in nature in one of two generally different environments, 
either as membrane bound or water-soluble forms.  Interestingly, pore-forming proteins 
have evolved and acquired a remarkable ability to be in either a soluble or membrane 
bound state.  Most of these pore-forming proteins require protein oligomerization for the 
transition from a soluble to a membrane-bound state.  Examples of pore-forming proteins 
include perforin and Bcl-2 family members, as well as several bacterial toxins.  Pore-
forming toxins are interesting not only because they might play an important role in the 
ability of bacteria to cause disease, but also because, like VacA, they could be used as 
models to study how pore-forming proteins undergo the transition from water-soluble to 
membrane bound forms.  Furthermore, analysis of the processes by which pore-forming 
toxins assemble into oligomeric structures may ultimately lead to the development of 
therapeutic inhibitors that block the oligomerization and the activity of these toxins in 
vivo. 
VacA effects on primary human T lymphocytes
Another important area of research is to try to identify the in vivo function or role 
of VacA in H. pylori infection.  H. pylori can persistently colonize the human gastric 
mucosa for decades despite the development of gastric mucosal inflammation and 
specific antibody production.  Several lines of evidence indicate that CD4+ T cells are 
critical for protection against H. pylori infection (2, 22, 41, 45).  Thus, it seems possible 
that immune evasion strategies of H. pylori virulence factors may involve the inhibition 
or modulation of T cell immunity.  VacA is an attractive candidate to modulate the 
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immune system since this protein is released from the bacteria into the extracellular 
environment (15).  This hypothesis is further supported by the ability of VacA to inhibit 
activation of Jurkat T cells (a human T cell lymphoma/leukemia cell line) as well as 
human peripheral blood lymphocytes (PBL) (this topic will be described in more detail in 
CHAPTER IV) (12, 34).  Furthermore, VacA has been shown to specifically inhibit the 
Ii-dependent pathway of antigen presentation mediated by major histocompatibility 
complex (MHC) class II (56).  Together, these studies indicate that VacA is capable of 
interfering with various steps in the immune response to H. pylori.  Infection with H. 
pylori causes the infiltration of neutrophils, T- and B-lymphocytes, plasma cells and 
macrophages to the site of infection, resulting in the extensive gastric mucosal 
inflammation observed in infected individuals (22, 41).  Most of the studies of VacA-
mediated effects on immune cells have been done using transformed cell lines (12, 34, 
56).  It is important to investigate VacA effects on primary human cells, which 
presumably are more appropriate for analyzing physiological responses to this toxin in 
vivo.  Therefore, another goal of this thesis was to investigate the effects of VacA on 
primary human CD4+ T cells.  Furthermore, VacA might serve as a tool like many other 
bacterial toxins (e.g. diphtheria, aerolysin, tetanus, and botulinum) to further dissect cell 
processes that were previously uncharacterized.  
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CHAPTER II 
 
INTERACTIONS BETWEEN P33 AND P55 DOMAINS OF THE 
HELICOBACTER   PYLORI VACUOLATING CYTOTOXIN 
 
Introduction 
The VacA toxin secreted by Helicobacter pylori     is considered to be an 
important virulence factor in the pathogenesis of peptic ulcer disease and gastric cancer 
(7, 30, 90).  VacA monomers self-assemble into water-soluble oligomeric structures 
comprised predominantly of 6 to 14 VacA monomers (1, 16, 46).  Assembly of VacA 
into oligomeric structures is required for cytotoxic effects, in particular for the formation 
of membrane channels (1, 40).  Thus far, the process by which VacA assembles into 
higher order structures has not been studied in any detail.  Therefore, the goal of this 
study was to characterize interactions that may mediate assembly of VacA into 
oligomeric structures.  The mature secreted 88 kDa VacA toxin can undergo spontaneous 
proteolytic degradation into fragments that are about 33 kDa and 55 kDa in mass (16, 
90).  It has been presumed that the two fragments (termed p33 and p55) represent two 
domains or subunits of VacA (16, 90).  The role of p33 and p55 domains in VacA 
assembly has not yet been study in any detail.  To facilitate the study of VacA assembly, 
a yeast two-hybrid system was used to investigate whether the p33 and p55 domains 
physically interact.   
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Methods 
Bacterial and yeast strains, media, and growth condition:  H. pylori strain 60190 
(ATCC 49503) was grown on Trypticase soy agar plates containing 5% sheep blood at 37 
oC in ambient air containing 5% CO2.  Liquid cultures were grown in sulfite-free brucella 
broth supplemented with either 5% fetal bovine serum or 0.5% activated charcoal.  
Escherichia coli XL1-Blue (Stratagene) was used for plasmid propagation and was 
grown on Luria-Bertani (LB) broth or LB agar at 37 oC.  Yeast two-hybrid experiments 
were performed with Saccharomyces cerevisiae strain YRG-2 (MAT α ura3-52 his3-200 
ade2-101 lys2-801 trp1-901 leu2-3,112 gal4-542 gal80-538 LYS2::UASGAL1 -
TATAGAL1-HIS3 URA3::UASGAL4 17mers(x3)-TATACYC1-lacZ) (Stratagene).  Yeast strains 
were grown in rich medium (yeast extract, peptone, dextrose [YPAD]) or in synthetic 
defined (SD) minimal medium (supplemented with required amino acids and glucose) at 
30 oC as described in the GAL4 Two-Hybrid Phagemid manual (Stratagene). 
 
Construction of yeast two-hybrid vectors containing vacA fragments:  vacA 
sequences encoding the wild-type p33 and p55 VacA domains were PCR-amplified from 
genomic DNA of H. pylori strain 60190 and cloned into plasmids encoding the 
transcription-activation domain (pAD) and/or the DNA-binding domain (pBD) of the 
GAL4 Two-Hybrid Phagemid system (Stratagene).  To facilitate the introduction of in-
frame deletion mutations into the pAD33 plasmid, vacA sequences encoding p33 mutant 
domains were PCR-amplified from genomic DNA of previously described H. pylori 
strains harboring the specific in-frame vacA deletions, and cloned into the pAD vector.  
vacA sequences encoding p55 fragments were PCR-amplified from genomic DNA of H. 
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pylori strain 60190 and were cloned into the pBD vector.  The entire vacA fragment in 
each p33 and p55 encoding plasmid was analyzed by nucleotide sequence analysis in 
order to verify that no unintended mutations had been introduced. 
 
Yeast methods:  Yeast strains were co-transformed with 400 ng of individual 
plasmids using the lithium acetate method and cultured on SD medium supplemented 
with the required amino acids and glucose at 30 °C as described in the GAL4 Two-
Hybrid Phagemid manual (Stratagene).  For a positive protein-protein interaction control, 
we co-transformed the yeast with pBD-WT and pAD-WT plasmids, which encode fusion 
proteins consisting of amino acids 132-236 of wild-type lambda cI, fragment C, together 
with either the GAL4- BD or AD, respectively.  For a negative control (i.e., two proteins 
that do not interact), we used the pAD-WT plasmid co-transformed with a pBD-pLamin 
C plasmid, which expresses the BD of GAL4 fused to amino acids 60-230 of human 
lamin C.  We also used plasmids pAD-Mut and pBD-Mut, which encode a mutated 
(E233K) lambda cI, fragment C, fused to either the GAL4- AD or BD.  The cI-E233K 
mutation interferes with the interaction between the cI monomers, resulting in a protein-
protein interaction that is weaker than that of wild-type proteins.  Plasmids expressing 
positive and negative interaction control proteins were obtained from Stratagene. 
One colony of each co-transformant was grown in 2 ml of SD medium containing 
2% (w/v) glucose and lacking Trp and Leu (SD-Leu,-Trp) at 30 °C with aeration for ~24 
h.  Cultures were then normalized to an OD600 of about 0.26 in a final volume of 100 µl 
of SD-Leu,-Trp,-Ηis broth, and 10-fold serially diluted into SD-Leu,-Trp,-Ηis broth in a 
micro-titer plate.  Diluted cultures (5 µl) were seeded on duplicate SD-Leu,-Trp plates 
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(selection for plasmids) and SD-Leu,–Trp,−Ηis plates (selection for protein-protein 
interactions) and incubated at 30 °C for 3-10 days. 
To confirm the occurrence of protein–protein interactions, a β-galactosidase 
liquid assay was performed using the Yeast β-Galactosidase Assay Kit as described by 
the manufacturer (Pierce).  Briefly, individual co-transformants were grown in 2 ml SD -
Leu,-Trp medium containing 2% (w/v) glucose at 30 °C with aeration for ~16-24 h until 
cultures reached mid-log phase (OD600 0.4-0.5).  150 µl aliquots of the cultures were then 
mixed with 150 µl of the working solution (equal volume of 2X β-Galactosidase Assay 
Buffer and Y-PERTM Reagent) and then incubated at 37 °C until solutions turned yellow 
(approximately 1-4 h), at which time reactions were stopped by the addition of 175 µl of 
β-Galactosidase Assay Stop Solution.  The time required for yellow color development 
was recorded for each tube. The OD410 of clarified reaction supernatants (200 µl) were 
measured in a 96-well plate and the β-galactosidase activity was calculated by using the 
Miller equation as described in the Yeast β-galactosidase Assay Protocol (Pierce).  The 
values presented are the average of at least three independent co-transformants (means + 
S.D.).  Statistical significance was analyzed using Student’s t test. 
 
Introduction of the FLAG-tag epitope and enterokinase-site into vacA:  To 
modify the vacA gene so that it encoded a VacA protein containing a FLAG-tag 
(DYKDADDDK) and an enterokinase cleavage site (after the underlined K), 
complementary primers encoding the FLAG epitope were annealed and ligated into the 
unique StuI site of plasmid pA178(50).  The resulting plasmid, pA178-FLAG, contained 
a sequence encoding the FLAG epitope in the proper orientation inserted between amino 
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acids 317 and 318 of VacA.  Plasmid pA178-FLAG was then used to transform H. pylori 
strain VM022 (100), and transformants were selected by growth on 5.5% sucrose plates 
(100).  Analysis of a single transformant (H. pylori VM088) by PCR and by DNA 
sequence analysis confirmed that the sequence encoding the FLAG epitope and the 
enterokinase cleavage site had been introduced into the desired location. 
 
Purification of oligomeric forms of VacA:  VacA was purified from broth culture 
supernatants of H. pylori (16).  Broth culture supernatant proteins were concentrated by 
precipitation with a 50% saturated solution of ammonium sulfate and resuspended in 
phosphate-buffered saline.  Oligomeric VacA (~1,000 kDa) was purified by gel-filtration 
chromatography using a Superose 6HR 16/50 column.  To analyze the oligomeric state of 
the enterokinase-treated FLAG-VacA, 40 µg of cleaved toxin was applied to a Superose 
6HR 16/50 column and fractions (2 ml each) were collected.  Fractions were analyzed by 
immunoblot analysis with an anti-VacA serum. 
 
Proteolysis of FLAG-VacA with enterokinase:  Purified FLAG-VacA was 
proteolytically cleaved with enterokinase as described by the Recombinant Enterokinase 
Kit manual (Novagen).  Briefly, 10 µg of purified FLAG-VacA was incubated with 1 unit 
of enterokinase and 5 µl of 10X enterokinase cleavage buffer in a final volume of 50 µl 
for >16 h at room temperature.  For mock treatment, FLAG-VacA was treated in the 
same manner, but without enterokinase.  Proteolysis of the full-length FLAG-VacA was 
assessed by immunoblot analysis using an anti-VacA serum or the M2 monoclonal anti-
FLAG antibody (Sigma).  
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 Cell culture and vacuolating assays:  HeLa cells were grown in minimal essential 
medium (modified Eagle’s medium containing Earle’s salts; MEM) supplemented with 
10% fetal bovine serum.  For vacuolating assays, HeLa cells were seeded (1.5 x 104) into 
96-well plates 24 h prior to each experiment.  Protein concentrations of the purified VacA 
toxins were determined by using a Micro-BCA assay (Pierce).  Purified VacA toxins 
(standardized by protein concentration) were incubated with cells in serum-free medium 
containing 10 mM ammonium chloride (15).  Purified VacA preparations (VacA, FLAG-
VacA and cleaved FLAG-VacA) were acid-activated by adjusting them to pH 3 by the 
addition of 250 mM hydrochloric acid before they were added to cell culture wells (21, 
53).  After 24 h incubation of VacA toxins with the cell monolayers, cells were examined 
by inverted light microscopy. Toxins that induced vacuoles in more than 50% of the cells 
were scored positive for vacuolating cytotoxic activity.  Vacuolating activity was 
quantified by a neutral red uptake assay and the data presented as OD540 values (means + 
S.D.).  
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Results 
 
p33 and p55 VacA domains interact in a yeast two-hybrid system 
 
 The 88 kDa VacA monomers commonly undergo spontaneous degradation into 
p33 and p55 VacA domains (Fig. 5) (16, 90).  To investigate potential interactions 
between these two VacA domains, we investigated whether they were able to interact in a 
yeast two-hybrid system (GAL4 Two-Hybrid Phagemid; Stratagene) (28).  In the yeast 
two-hybrid system, the yeast GAL4 transcription activator protein has been divided into 
two separate functional domains(47): (i) the transcription-activation domain (AD) present 
on plasmid pAD-GAL4-2.1 (pAD), which encodes for the LEU2 gene as a selectable 
marker, and (ii) the DNA-binding domain (BD) present on the plasmid pBD-GAL4-Cam 
(pBD), which encodes for the TRP1 gene as a selectable marker.  Proteins of interest are 
then fused to either the GAL4-AD or the BD domains and if two fusion proteins interact, 
they will bring in close proximity the GAL4 transcription-activation domain and the 
GAL4 DNA-binding domain to the GAL4/GAL1 promoter, which in turn, will initiate 
the transcription of the HIS3 and lacZ reporter genes.  Protein-protein interactions are 
then detected by the ability of co-transformed yeast cells to grow in selective medium 
lacking Leu, Trp, and His (SD-Leu,-Trp,-His) and by production of β-galactosidase 
activity. 
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Figure 5.  Proteolytic degradation of VacA into 33 and 
55 kDa fragments.  Proteins precipitated from broth culture 
supernatant of H. pylori 60190 by a 50 % saturated solution of 
ammonium sulfate (lanes A and B) or purified VacA (lanes C and 
D) from H. pylori 60190 were electrophoresed on a 10% SDS-
polyacrylamide gel, transferred to a nitrocellulose membrane and 
immunobloted with polyclonal anti-VacA serum. These 
preparations exhibit varying degrees of spontaneous VacA 
proteolysis into p33 and p55 fragments. 
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vacA sequences encoding the p33 and p55 VacA domains were cloned into 
plasmids encoding the GAL4-AD (pAD) and the BD domains (pBD), generating 
plasmids pAD33, pBD33, pAD55 and pBD55.  To test whether interactions between p33 
and p55 VacA domains could be detected in this system, we co-transformed all four 
possible combinations of the p33 and p55 yeast two-hybrid plasmids into the yeast 
reporter strain (Fig. 6A).  Serial dilutions of co-transformed yeast were then tested for 
their ability to grow on synthetic defined (SD) minimal medium lacking Leu and Trp 
(SD-Leu and -Trp), as well as SD medium lacking Leu, Trp, and His (SD-Leu, -Trp, and 
-His).  All of the co-transformed yeast grew on the former media, which confirmed that 
the transformation had been successful and provided an indication of the relative number 
of co-transformed yeast cells present in each dilution.  Yeast co-transformed with 
plasmids encoding p33 and p55 fusion proteins grew in SD medium lacking Leu, Trp, 
and His, indicating that the p33 and p55 domains interact in this system (Fig. 6B).  In 
contrast, yeast co-transformed with plasmids encoding p33/p33 or p55/p55 fusion 
proteins did not grow on SD medium lacking Leu, Trp and His, suggesting that they did 
not interact (Fig. 6B).  The ability of p33 and p55 to interact was further confirmed by the 
analysis of β-galactosidase activity, which reflects the activation of the lacZ reporter gene 
(Fig. 6C).  The p33/p55 interaction was independent of the protein fused (AD or BD) to 
the p33 or p55 fragment, since both combinations of tested plasmids (pAD33/pBD55 and 
pAD55/pBD33) were able to activate the HIS3 and lacZ reporters (Fig. 6; panels B and 
C).  
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Figure 6.  Interaction of VacA fragments in the yeast two-hybrid 
system.  A) Representation of the different p33 and p55 fusion proteins and 
plasmid combinations used in the co-transformation experiments.  B) Yeast cells 
were co-transformed with the plasmids depicted in panel A, or with controls 
plasmids described in the Methods section.  Co-transformed yeast-cells 
(normalized based on OD) were 10-fold serially diluted and identical inocula 
were plated on two types of SD agar plates.  All of the co-transformed yeast grew 
on SD-Leu,-Trp plates.  Protein-protein interactions were assessed by growth of 
the co-transformed yeast cells on SD-Leu,-Trp,-His plates.  C)  β-galactosidase 
liquid culture assay of the co-transformed yeast-cells.  Activation of the protein-
protein interaction reporters were only detected when yeast were co-transformed 
with plasmids encoding wild-type p33 together with a plasmid encoding wild-type 
p55.  Results represent the mean + S.D. from triplicate determinations, each 
representing a separate colony.  * = P (<0.05) when compared to the negative 
control.  + cntrl = positive control, - cntrl = negative control. 
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Disruption of the p33/p55 interaction correlates with the lack of VacA  
oligomerization and vacuolating activity 
 
  In a previous study, several H. pylori mutant strains containing in-frame deletion 
mutations in the vacA gene were constructed and analyzed (Fig. 7A) (100).  Results from 
this previous study indicated that a mutant VacA protein with a deletion of amino acids 
6-27, VacA-(∆6-27), could assemble into water-soluble oligomeric structures, and 
suggested that VacA proteins containing ∆28-108, ∆56-83, ∆85-127, or  ∆112-196 
deletion mutations were defective in the capacity for oligomer assembly (Fig. 7A) (100).  
We hypothesized that the latter mutations might disrupt the p33/p55 interaction, and that 
such a defect might account for the failure of these VacA mutant proteins to form 
oligomeric structures.  In order to directly test this hypothesis, we introduced these same 
deletion mutations (i.e., ∆6-27, ∆28-108, ∆56-83, ∆85-127 and  ∆112-196) into the 
pAD33 plasmid.  Wild-type pAD33 and pAD∆6-27p33 were each able to activate both 
the HIS3 and lacZ reporter genes when co-transformed with wild-type pBD55, whereas 
the other pAD33 mutants failed to activate the reporter genes when co-transformed with 
wild-type pBD55 (Fig. 7; panels B and C).  Thus, mutations that impair p33/p55 
interactions also block oligomerization of VacA secreted by H. pylori (100). 
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Figure 7.  Interaction between wild-type p55 and p33 mutant 
VacA fragments.  A)  Diagram of in-frame deletion VacA mutant proteins 
produced in H. pylori.  Oligomer formation of full-length VacA toxins 
secreted by H. pylori was analyzed by determining whether these proteins 
eluted as large oligomeric structures (~1,000 kDa) from a Superose 6 HR 
16/50 FPLC column.  Cytotoxic vacuolating activity of VacA toxins was 
assessed by intoxicating HeLa cells.  B) Co-transformed yeast-cells 
(normalized based on OD) were 10-fold serially diluted and identical 
inocula were plated on two types of SD plates.  Protein-protein 
interactions were assessed by growth of the co-transformed yeast cells on 
SD-Leu, -Trp, -His plates.  C) β-galactosidase liquid culture assay of the 
co-transformed yeast-cells.  Activation of the protein-protein interaction 
reporters were only detected when yeast were co-transformed with 
plasmids encoding wild-type p-33 or ∆6-27p33 together with a plasmid 
encoding wild-type p55.  Results represent the mean + S.D. from triplicate 
colonies.  * = P (<0.05) when compared to the negative control.   
 29
The N-terminus of the p55 domain is the minimum p55 fragment  
able to interact with p33 
 
To further map putative amino acid sequences involved in the p33/p55 
interaction, we generated different p55 fragments (i.e., encoding amino acids: 313-700, 
313-550, 313-478, 550-821, and 479-821) and cloned them into the pBD vector (Fig. 
8A).  These new fusion proteins were tested for their ability to interact with wild-type 
p33 as described above.  Yeast co-transformed with the pAD33 plasmid and plasmids 
expressing p55 fragments containing amino acids 313-700, 313-550, or 313-478 were 
able to grow on SD-Leu,-Trp,-His, whereas yeast co-transformed with the pAD33 
plasmid and plasmids expressing p55 fragments containing amino acids 479-821 or 550-
821 were not able to grow (Fig. 8B).  The former group of co-transformed yeast grew 
slowly on SD-Leu,-Trp,-His plates and expressed a relatively low level of β-
galactosidase activity (Fig. 8; panel B and C).  This suggests that the interactions between 
the 313-700, 313-550 and 313-478 p55 fragments and p33 are weaker than the interaction 
between full-length wild-type p55 and p33.  When we co-transformed yeast with a 
mutated version of the positive control plasmids (Mutant + control described in the 
Methods section) known to encode proteins that interact with relatively low affinity, a 
similar low level of β-galactosidase activity was detected (Fig. 8C).  The data obtained 
with these mutant control plasmids supports our conclusion that the p33 interacts weakly 
with 313-700, 313-550, and 313-478 p-55 fragments.  
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Figure 8.  Interaction between wild-type p33 and fragments of p55.  
(A) Representation of the different p55 fragments used in the co-transformation 
experiment. (B)  Yeast-cells co-transformed with the pBD55 fragments depicted 
in panel A and wild-type pAD33 (normalized based on OD) were 10-fold serially 
diluted and identical inocula were plated on two types of SD agar plates.  (C)  β-
galactosidase liquid culture assay of the co-transformed yeast-cells.  Protein-
protein interactions were assessed by growth of the co-transformed yeast cells on 
SD-Leu,-Trp,-His plates and by a β-galactosidase liquid culture assay.  Sample 
numbers in panel C are identical to those in panel B.  Wild-type p33 was able to 
interact with p55 fragments containing amino-acids 313-700, 313-550 and 313-
478 but not with amino acids 550-821 or 479-821. β-galactosidase liquid culture 
assay results represent the mean + S.D. from triplicate colonies.  * = P (<0.05) 
when compared to the negative control.  
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Proteolytic cleavage of a modified VacA protein results in the generation of 
the p33 and p55 domains 
 
We sought to confirm the finding that p33 interacts with p55 using VacA purified 
from H. pylori.  Several previous studies have demonstrated that VacA proteins produced 
by H. pylori can degrade into 33 kDa and 55 kDa fragments (p33 and p55 respectively) 
(16, 90).  However, it remains unclear whether proteolytic cleavage of the 88 kDa VacA 
protein into p33 and p55 fragments alters VacA cytotoxic activity or alters its oligomeric 
structure.  One reason why this issue has not yet been addressed in any detail is that it has 
been difficult to experimentally induce the desired cleavage.  VacA preparations 
commonly undergo partial proteolytic degradation during storage (Fig. 5), but complete 
proteolysis of the 88 kDa VacA protein into smaller fragments occurs uncommonly.  
Furthermore, spontaneous proteolytic degradation of VacA often involves cleavage at 
multiple sites. 
In order to test experimentally whether cleavage of VacA into p33 and p55 
domains alters its activity, we sought to develop a system in which a protease could be 
used to induce proteolytic cleavage at a specific site located between the p33 and p55 
domains.  To accomplish this, we constructed a modified H. pylori strain in which an 
oligonucleotide encoding the FLAG-tag epitope and an enterokinase cleavage site was 
inserted into the vacA allele of H. pylori 60190 resulting in H. pylori VM088 strain (Fig. 
9).   
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Figure 9.  Construction of H. pylori VM088 using a sacB-based 
counter-selection approach.  (A) The pMM389 plasmid contains a vacA 
fragment from H. pylori strain 60190 and a sacB / kan cassette.  
Transformation of H. pylori 60190 with pMM389 yielded a kanamycin-
resistant transformant designated H. pylori VM022.  H. pylori VM022 was 
transformed with pA178-FLAG plasmid, transformants selected on 
sucrose-containing medium, and a strain (H. pylori VM088) with a 
sequence encoding a FLAG-tag with an enterokinase site inserted into the 
vacA gene was thereby obtained.  (B) VacA spontaneously degrades into 
two fragments, termed p33 and p55.  Open arrows indicate the most 
common site at which wild-type VacA from H. pylori 60190 undergoes 
spontaneous cleavage and the resulting p33 and p55 fragments.  Closed 
arrows indicate the enterokinase cleavage site introduced with the FLAG-
tag epitope and the FLAGp33 and p55 fragments generated after 
enterokinase cleavage.  The amino acid numbering system used in this 
figure is based on designating the first amino acid (alanine) of the mature 
secreted VacA toxin of strain 60190 as amino acid 1. 
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This enterokinase cleavage site provided a mechanism by which the 88 kDa VacA 
protein could be specifically cleaved into fragments similar to the spontaneously arising 
33 kDa and 55 kDa VacA fragments.  The FLAG-VacA toxin was purified from H. 
pylori VM088 culture supernatant and underwent spontaneous partial degradation into 
two forms of the p33 and p55 VacA fragments (Fig. 10A and B), which is consistent with 
previous observations suggesting that proteolysis can occur at multiple sites.  As 
expected, enterokinase treatment resulted in the complete cleavage of the full-length 
FLAG-VacA into p55 and FLAG-tagged p33 (FLAGp33) fragments as seen by 
immunoblot analysis using an anti-VacA serum or an anti-FLAG monoclonal antibody 
(Fig. 10A and B).    
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Figure 10.  Characterization of the FLAG-VacA.  Purified VacA 
from H. pylori VM088 (10 µg) was either treated with enterokinase (1 Unit) 
or mock treated.  Toxins (100 ng) were then electrophoresed on a 10% SDS-
polyacrylamide gel, transferred to a nitrocellulose membrane and reacted with 
anti-FLAG M2 monoclonal antibody (Sigma) (A).  The blot was then stripped 
and reacted with polyclonal anti-VacA serum (B).  Enterokinase treatment 
induced complete cleavage of full-length FLAG-VacA into ~33 and ~55 kDa 
fragments.  In preparations of FLAG-VacA not treated with enterokinase, the 
FLAG-tag epitope is detected predominantly in full-length 88 kDa VacA and 
in the p55 fragment (Figure 6A lane 1).  Only the ~33 kDa fragment retained 
the FLAG-tag epitope after enterokinase treatment (Panel A lane 2).  C) 
Identical aliquots of purified FLAG-VacA were either treated with 
enterokinase as described above or left untreated.  Toxins (5 µg/ml) were then 
either acid activated (pH 3) or left untreated and added to tissue culture 
medium overlying HeLa cells.  Vacuolating activity was quantified using a 
neutral red uptake assay.  Enterokinase-treated FLAG-VacA and untreated 
FLAG-VacA did not differ significantly in vacuolating cytotoxin activity.  
Furthermore, both enterokinase-treated and untreated FLAG-VacA required 
acid activation in order to induce vacuolating activity.  Results represent the 
mean + S.D. from triplicate samples and are expressed as a percent of neutral 
red uptake induced by full-length acid-activated FLAG-VacA. 
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 Proteolytically cleaved VacA exhibits vacuolating activity  
similar to that of full-length VacA 
 
We next compared the cytotoxic activities of intact FLAG-VacA and FLAG-
VacA that had been proteolytically cleaved into p55 and FLAGp33 fragments.  Purified 
oligomeric FLAG-VacA was either treated with enterokinase or mock treated as 
described in In the Methods section.  Proteins were then acid activated (a procedure used 
to enhance vacuolating activity) (21, 53) and added to the neutral-pH medium overlying 
HeLa cells.  The vacuolating activities of intact FLAG-VacA and proteolytically cleaved 
FLAG-VacA were indistinguishable as determined a neutral red uptake assay (Fig. 10C).   
VacA purified from wild-type H. pylori strain 60190 exhibits very little 
vacuolating toxic activity unless it is acid- or alkaline-activated prior to contact with cells 
(21, 53, 108).  This acid- or alkaline activation induces the disassembly of the VacA 
oligomer into monomeric proteins, suggesting perhaps that VacA needs to be in a 
monomeric form to bind to mammalian cells and to form active channels.  We 
hypothesized that proteolytically cleaved VacA might exhibit vacuolating toxic activity 
even in the absence of acid-activation.  However, neither intact nor proteolytically 
cleaved FLAG-VacA exhibited detectable vacuolating activity in the absence of acid 
activation, as determined by a neutral-red uptake assay (Fig. 10C).   
 
 Proteolytically cleaved VacA forms oligomeric structures similar to full-length 
VacA  
 
The secreted FLAG-VacA assembles into large water-soluble oligomeric 
structures, in a manner similar to wild-type VacA (Fig. 11A) (16).  To determine whether 
the p33 and p55 domains remained physically associated following proteolytic cleavage 
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of FLAG-VacA, enterokinase-treated FLAG-VacA was fractionated by gel filtration 
chromatography (16), and its elution pattern monitored by immunoblot analysis with an 
anti-VacA serum.  Proteolytically cleaved FLAG-VacA and intact FLAG-VacA were 
found to elute in the same high molecular mass fractions (Fig. 11; compare panels A and 
B), indicating that VacA fragments (i.e. FLAGp33 and p55) remain physically associated 
within an oligomeric structure. 
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Figure 11.  Oligomeric state of full-length FLAG-VacA and 
cleaved FLAG-VacA.  Concentrated broth culture supernatant from 
Helicobacter pylori     strain VM088 (A) and 40 µg of purified FLAG-
VacA treated with enterokinase as described in In the Methods section 
(B), were applied to a Superose 6 HR FPLC column (16).  Forty fractions 
of 2 ml each were collected, with fraction 1 corresponding to the void 
volume.  Samples (40 µl) were then electrophoresed on a 10% SDS-
polyacrylamide gel, transferred to a nitrocellulose membrane and 
immunoblotted with anti-VacA serum.  Full-length VacA as well as 
enterokinase-cleaved VacA eluted in the same fractions with an elution 
peak at fraction 13, corresponding to a molecular mass of about 1,000 
kDa.  The p55 fragments are detected more prominently than p33 
fragments in panel B due to the relatively weaker reactivity of the anti-
VacA serum against the p33 fragment.   
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Discussion 
 
Although many lines of evidence indicate that VacA can form oligomeric 
structures (1, 16, 46, 100), thus far there has been relatively little investigation of the 
specific VacA-VacA interactions that are required for its assembly into higher order 
structures.  In this study we investigated the role of p33 and p55 interactions in VacA 
oligomerization.  We demonstrated that only heterotypic interactions between p33 and 
p55 were detected using the yeast two-hybrid system (Fig. 6).  The lack of detectable 
p33/p33 and p55/p55 homotypic interactions was not due to the lack of expression of 
these fusion proteins in the yeast, since all four fusion proteins were able to interact when 
tested for p33/p55 interactions (Fig. 6).  Importantly, the failure to detect p33/p33 or 
p55/p55 interactions in the yeast two-hybrid system does not exclude the possibility that 
such interactions might occur in other environments.  Previously it has been reported that 
a modified p55 fragment secreted by H. pylori can form homodimers but not large 
oligomeric structures (76).  However, the VacA protein analyzed in that study contained 
at least 27 residues of the p33 domain in addition to the p55 fragment (76).  In addition, 
another previous study provided evidence that an amino-terminal hydrophobic portion of 
the p33 fragment could undergo transmembrane protein homodimerization within E. coli 
membranes (49).  The inability to detect p33/p33 interactions with the yeast two-hybrid 
system is consistent with a model in which p33/p33 interactions occur only within 
membranes (49, 52). 
In an effort to map putative interacting regions within p33 and p55, we used the 
yeast two-hybrid system to analyze a series of mutant proteins containing internal 
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deletions, as well as truncated VacA proteins Fig. 7 and 8) (100).  The yeast two-hybrid 
data suggest that amino acids 28-196 within the p33 domain and 313-478 within the p55 
domain contribute to the p33/p55 interaction.  Only one of the p33 deletion mutants (∆6-
27p33) was able to interact with wild-type p55.  VacA amino acids 6-27 comprise a 
hydrophobic region of VacA that inserts into lipid membranes and is required for VacA 
cytotoxic and membrane anion-channel activity, but not for VacA oligomerization (100).   
By constructing an enterokinase sensitive VacA toxin (Fig. 10), which can be 
efficiently cleaved into p33 and p55 domains, we were able to study the p33/p55 
interactions that occur within the VacA oligomer produced by H. pylori.  Our results 
clearly indicate that p33 and p55 fragments remain physically associated after proteolytic 
cleavage of VacA (Fig. 11).  Furthermore, our results also demonstrate that the 
vacuolating activity of intact FLAG-VacA and fully proteolytically cleaved FLAG-VacA 
is indistinguishable (Fig. 10C).  A likely explanation for the intact activity of 
proteolytically cleaved VacA is that the fragments remain associated and do not undergo 
any extensive adverse conformational changes (unfolding) following proteolytic 
cleavage.  
Two lines of evidence presented in the current study suggest that the p33/p55 
interactions play an important role in VacA oligomer assembly.  First, the intact 
oligomeric structure of proteolytically-cleaved VacA indicates that p33/p55 interactions 
occur within VacA oligomers (Fig. 11B).  Second, the properties of mutant p33 
fragments in the yeast two-hybrid system correlate perfectly with the capacity of secreted 
H. pylori mutant proteins to form oligomeric structures (Fig. 7).  Together, these data 
suggest that mutations disrupting the p33/p55 interaction also disrupt the formation of 
 40
large VacA oligomeric structures.  It is possible that there may be two different types of 
interactions: (i) intramolecular interactions between the p33 and p55 domains of an 
individual VacA monomer that might be important for proper folding of the VacA 
monomers within the oligomeric structures and (ii) intermolecular interaction between 
p33 and p55 domains of different 88 kDa molecules to form the larger oligomeric 
structures.  Currently, we are not able to differentiate between these two interactions.   
VacA toxins that fail to oligomerize consistently lack vacuolating cytotoxic 
activity, suggesting that oligomerization is important for VacA activity (Fig. 7A) (100).  
This hypothesis is supported by the observation that neither p33 nor p55 are able to 
exhibit vacuolating cytotoxic activity in a transient transfection assay when expressed 
individually within cells (20, 111, 113).  In contrast, when both domains are co-expressed 
within cells, they interact and exhibit vacuolating cytotoxic activity (111, 113).  Thus, the 
data presented in the current study, as well as data obtained using other systems, indicate 
that p33/p55 interactions are essential for VacA assembly into oligomeric structures and 
also for vacuolating cytotoxic activity. 
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CHAPTER III 
 
FUNCTIONAL PROPERTIES OF THE P33 AND P55 DOMAINS OF THE 
HELICOBACTER PYLORI     VACUOLATING CYTOTOXIN 
 
Introduction 
Helicobacter pylori secretes a vacuolating cytotoxin (VacA) that induces 
extensive vacuolating activity on mammalian cells (15, 43).  In order for VacA to be 
cytotoxic, it must bind to the plasma membrane and then be internalized by host cells 
(53).  The mature secreted 88 kDa VacA toxin can undergo proteolytic degradation into 
two fragments, p33 and p55, which are considered to be two VacA domains (90, 94).  
However, detailed analyses of the functional roles of p33 and p55 domains in VacA 
activities have not yet been performed.  One of the major constraints during the past 
decade in efforts to investigate VacA structure-function relationships has been the lack of 
a recombinant expression system to produce active VacA proteins.  Recently, McClain 
and Cover described a methodology to express functionally active full-length VacA 
proteins using an E. coli expression system (51).  In the current study, this recombinant 
methodology was used to produce recombinant p33 and p55 VacA proteins.  These 
recombinant VacA proteins were then used to investigate the role of p33 and p55 
domains in several processes relevant to VacA intoxication.   
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 Methods 
Bacterial, media, and growth condition:  Escherichia coli DH5α was used for 
plasmid propagation and was grown in Luria-Bertani (LB) broth or LB agar at 37 °C.  
For expression of the recombinant proteins, expression plasmids were transformed into E. 
coli strain JM109-DE3 (Stratagene), which encodes an isopropyl-ß-D-
thiogalactopyranoside (IPTG)-inducible copy of the T7-RNA polymerase gene from 
bacteriophage T7.  Transformants were grown in Terrific broth (TB; Invitrogen) 
supplemented with 25 µg of kanamycin/ml (TB-KAN). 
 
Construction of VacA expression plasmids:  A vacA sequence encoding the VacA 
p33 domain (amino acids 1-312 of the mature secreted toxin) with a 6-His tag at the C-
terminus was PCR-amplified from the pMM592 plasmid (51).  The PCR product was 
digested with SpeI and SalI and ligated into XbaI- and SalI-digested pET-41b (conferring 
kanamycin resistance; Novagen) to create the plasmid p145 (p33His).  We also generated 
a plasmid that encoded a VacA p33 domain with two tags (c-Myc and 6-His), each at the 
carboxyl-terminus of the protein (p33Myc-His).  
A vacA sequence encoding the p55 domain (amino acid 312-821) with a c-Myc 
tag (p55Myc) at the amino-terminus was PCR-amplified from H. pylori VT320 genomic 
DNA (50).  Also, a vacA sequence encoding the p55 domain with a 6-His tag at the N-
terminus was PCR-amplified from the pMM592 plasmid (51).  PCR products were 
digested and cloned into pET-41b as described above.  Also, 6-His tagged-p55 fragments 
encoding amino acids 312-780, 312-700, 312-550, and 312-478 were PCR-amplified 
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from the pMM592 plasmid.  The PCR products were digested and cloned into pET-41b 
as described above.   
 
Expression of recombinant VacA proteins:  VacA expression plasmids were 
transformed into the E. coli expression strain JM109-DE3, and transformants were then 
inoculated into TB-KAN and grown at 37 °C overnight with shaking (51).  Cultures were 
then diluted 1:100 into TB-KAN, and incubated at 37°C until they reached an optical 
density (OD600) of 0.5.  Cultures were then induced with a final IPTG concentration of 
0.5 mM and incubated at 25 °C for 16-18 h (p55 proteins and full-length VacA proteins) 
or at 37oC for 2 h (p33 proteins).  E. coli soluble extracts were generated as described by 
McClain et at (51).  Briefly, 50 ml of IPTG-induced cultures were pelleted, washed in 
0.9% NaCl, and resuspended in a solution (1 ml) that contained 10 mM Tris (pH 7.5), 100 
mM NaCl, 1 mM EDTA, protease inhibitors (Complete Mini; Roche), and 20,000 U of 
ReadyLyse lysozyme (Epicentre) per ml.  Bacteria cells were incubated on ice for 30 min 
with periodic mixing, after which a solution (3 ml) containing 50 mM Tris (pH 8.0), 2.67 
mM MgCl2, and 67 U of Benzonase-nuclease (Novagen) per ml was added.  Samples 
were then mixed briefly and subjected to four successive rounds of freezing (in a dry ice-
methanol bath) and thawing at 37°C, and the insoluble debris was pelleted.  The E. coli 
soluble extracts containing the VacA proteins were collected and stored at -20 °C until 
use. 
 
Immunoblot analysis of recombinant VacA:  E. coli soluble extracts containing the 
VacA proteins were generated as described above and the proteins were separated by 
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SDS-polyacrylamide gel electrophoresis, transferred to nitrocellulose, and 
immunoblotted using a polyclonal anti-His antibody (Santa Cruz), a monoclonal anti-c-
Myc (9E10) antibody, or a polyclonal anti-VacA antibody (958), and secondary 
antibodies conjugated with horseradish peroxidase (Bio-Rad).  Signals were generated by 
the enhanced chemiluminescence reaction (Roche) and detected using x-ray film.  For 
subsequent experiments, E. coli soluble extracts were normalized to contain similar 
amounts of recombinant VacA proteins based on densitometry analysis of the x-ray films.  
 
Cell culture and vacuolating assays:  HeLa cells were grown in minimal essential 
medium (modified Eagle’s medium containing Earle’s salts; MEM) supplemented with 
10% fetal bovine serum.  For vacuolating assays, HeLa cells were seeded into 96-well 
plates 24 h prior to each experiment.  To test the E. coli soluble extracts for vacuolating 
activity, aliquots of each extract were normalized to contain similar amounts of 
recombinant VacA protein by immunoblotting with an anti-His antibody as described 
above, and then samples were added to the medium overlying HeLa cells (supplemented 
with 50 µg per ml of gentamicin and 10mM ammonium chloride) for 1 h (15).  For the 
p33/p55 complementation assays, E. coli soluble extracts were mixed and incubated for 1 
h at room temperature prior to addition to the medium overlying HeLa cells.  For 
experiments in which p33 and p55 samples were added sequentially to cells, lysate 
containing the first VacA protein was added to the cells and incubated for 1h.  After 
incubation, the cells were washed two times to remove unbound proteins and lysate 
containing the second VacA protein was then added for an additional 1h.  Cells were then 
washed two more times and  the culture media overlying cells was replaced with fresh 
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culture media and incubated for 4-6 h at 37 oC.  Purified VacA from H. pylori culture 
supernatants was acid-activated by adjusting the VacA protein to pH 3 by the addition of 
250 mM hydrochloric acid before they were added to cell culture wells (21), whereas E. 
coli lysates were not acid-activated.  In all vacuolating assays, the medium overlaying 
HeLa cells was supplemented with 10mM ammonium chloride and gentamicin.  After 
incubation, cells vacuolation was examined by inverted light microscopy and quantified 
by a neutral red uptake assay as described previously.  Neutral red uptake data are 
presented as OD540 values (means + S.D.).  Statistical analysis was made by ANOVA and 
Dunnett’s post-hoc test.   
 
Immunoprecipitation of VacA complexes:  E. coli soluble extracts, normalized to 
contain similar amounts of recombinant VacA proteins, were mixed and incubated for 1 h 
as described above.  VacA complexes were then immunoprecipitated with an anti-c-Myc 
monoclonal antibody (2 µg of clone 9E10) and protein G coated-beads.  
Immunoprecipitated proteins were separated by SDS-polyacrylamide gel electrophoresis, 
transferred to nitrocellulose, and immunoblotted with an anti-His (Santa Cruz) antibody 
or anti-c-Myc monoclonal antibody, and secondary antibodies conjugated with 
horseradish peroxidase (Bio-Rad).  Signals were generated by the enhanced 
chemiluminescence reaction (Roche) and detected using x-ray film.  
 
Analysis of VacA binding and internalization into mammalian cells:  Normalized 
E. coli soluble extracts containing single recombinant VacA proteins or mixtures of the 
recombinant VacA proteins were incubated for 1h as described above, and samples were 
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then added to HeLa cells grown on cover glasses in 6 well plates for 1h at 37 oC.  VacA 
interactions with mammalian cells were then analyzed by indirect immunofluorescence.  
Briefly, cells were washed with tris-buffered saline (TBS) and fixed with 3.7% 
formaldehyde.  Fixed cells were then incubated with an anti-c-Myc antibody (1:500) or 
with an anti-VacA polyclonal antibody (958) that recognizes the p55 domain, for 1 h at 
room temperature (81).  Cells were then washed and incubated with a Cy3-conjugated 
secondary antibody (1:500) for 1 h at room temperature.  To analyze VacA 
internalization into host cells, E. coli soluble extracts containing single recombinant 
VacA proteins or mixtures of recombinant VacA proteins were treated as described above 
and then incubated with HeLa cells for 1h at 37 oC (44).  Afterward, the medium was 
changed and cells were incubated for 12-16 h at 37 oC.  VacA intoxicated cells were then 
washed with TBS, fixed with 3.7% formaldehyde, and permeabilized with 100% 
methanol for 30 minutes at -20 oC.  Cells were then incubated with an anti-VacA 
polyclonal or an anti-c-Myc antibody followed by a Cy3-conjugated secondary antibody.  
After immunolabeling, cover glasses were washed with phosphate-buffered saline, 
mounted on slides with Aqua-Polymount (Polysciences, Warrington, PA), and viewed 
with a LSM 510 confocal laser scanning inverted microscope (Carl Zeiss, Jena, 
Germany) (44).  
For immunoblot analysis of VacA interaction with cells, HeLa cells were seeded 
into a 96-well plate and intoxicated with normalized E. coli soluble extracts as described 
above.  Cells were then washed three times with TBS and then lysed directly in the wells 
of the 96-well plate by adding SDS-loading buffer.  Proteins were then analyzed by 
immunoblotting as described above. 
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Results 
 
Expression of recombinant p33 and p55 VacA domains
Purified 88 kDa VacA protein from H. pylori culture supernatant can undergo 
proteolysis into two fragments designated as p33 and p55 VacA domains (Fig. 12A) (90, 
94).  Currently, there are only several systems that can be used to study p33 and p55 
structure and function.  These systems include transient transfection assays (20, 107), 
yeast two-hybrid analysis (94) and analysis of purified toxins from H. pylori broth culture 
supernatants (15).  Among these systems, only analysis of proteins produced by H. pylori 
allows for the study of VacA-cell interactions, but structure-function analysis of VacA 
using the H. pylori system is cumbersome and in some cases impossible.  To enable 
further functional studies of the p33 and p55 domains, we adapted the VacA expression 
methodology reported by McClain and Cover (i.e. a methodology that allows for the 
expression of functionally active recombinant VacA proteins) to produce recombinant 
p33 and p55 VacA proteins (51).  The vacA sequences encoding the p33 and p55 were 
cloned into the pET-41b E. coli expression plasmid.  The plasmids were then transformed 
into an E. coli expression strain, recombinant proteins were expressed, and soluble 
extracts containing the recombinant p33 and p55 VacA proteins were generated as 
described in the Methods section (Fig. 12B).   
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Figure 12.  Expression of the p33 and p55 VacA domains in E. 
coli.  A) Diagram of the mature secreted ~88 kDa wild-type VacA protein 
(p88) and the ~33 kDa (p33) and ~55 kDa (p55) VacA domains.  The p33 
domain is comprised of amino acids 1-312 and the p55 domain is 
comprised of amino acids 313-821.  The VacA amino acid numbering 
system used in this figure is based on designating the first amino acid 
(alanine) of the mature secreted VacA toxin of Helicobacter pylori     
strain 60190 as amino acid 1.  B) Plasmids encoding His-tagged VacA p33 
or p55 domains were transformed into the E. coli expression strain 
(JM109-DE3).  Proteins were expressed and soluble extracts containing 
the VacA proteins were generated as described in the Methods section.  
Soluble proteins were electrophoresed on a 12% SDS-polyacrylamide gel, 
transferred to a nitrocellulose membrane and immunoblotted with an anti-
His antibody (Santa Cruz).   
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p33 and p55 VacA domains complement each other for vacuolating activity
Previously, it has been shown that E. coli soluble extract containing the full-
length wild-type recombinant VacA exhibits vacuolating activity when added to 
mammalian cells (51).  Therefore, we used E. coli soluble extract containing the p33 and 
p55 proteins to investigate whether these VacA proteins were also capable of inducing 
vacuolating activity when added to mammalian cells.  No detectable vacuolating activity 
was observed when HeLa cells were intoxicated with lysates containing p33 or p55 
proteins (Fig. 13).  We then investigated whether the p33 and p55 proteins could 
complement each other for vacuolating activity.  Accordingly, E. coli soluble extracts 
containing the p33 and p55 proteins were mixed and then added to HeLa cells.  When 
mixed together the p33 and p55 VacA proteins exhibited extensive cell vacuolation, as 
evidenced by the increase in neutral red uptake (Fig. 13A).  The vacuolating activity 
exhibited by the p33/p55 mixture was comparable to the activity exhibited by 10 µg/ml 
of purified acid-activated VacA from H. pylori broth culture supernatant.  Similar 
extensive vacuolating activity was also observed when a gastric cell line (i.e. AZ-521), 
was intoxicated with the p33/p55 mixture instead of HeLa cells (Fig 13B).  As seen with 
purified VacA, the vacuolating activity exhibited by the mixture of the recombinant p33 
and p55 VacA domains was dose-dependent (Fig 13C).  These results indicate that 
recombinant p33 and p55 VacA domains are capable of complementing each other, 
resulting in vacuolating cytotoxic activity.   
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Figure 13.  The recombinant p33 and p55 VacA domains exhibit vacuolating 
activity when combined, but not when added alone to mammalian cells.  A) E. coli 
soluble extracts containing single recombinant p33His and p55His VacA proteins, 
negative control lysate without VacA protein (pET), or a mixture of extracts containing 
the p33 and p55 domains were added to HeLa cells as described in the Methods section.  
Lysates were normalized by densitometry analysis of the immunoblot x-ray films, such 
that the relative amounts of p33 and p55 domains were approximately equivalent.  
Vacuolating activity was measured by a neutral red uptake assay.  Results represent the 
mean + standard deviation from triplicate samples, expressed as a percent of neutral red 
uptake induced by 10 µg/ml of full-length acid-activated VacA toxin purified from H. 
pylori culture supernatant.  Comparisons between each sample and the pET control were 
made by ANOVA and Dunnett’s post-hoc test.  Asterisks denote results significantly 
different from control (p<0.05).  These data suggest that both the p33 and p55 domains 
are required for VacA cytotoxic activity.  B) HeLa and AZ-521 cells were intoxicated 
with the p33 and p55 proteins as described in panel A.  Vacuolating activity was 
measured by a neutral red uptake assay, and results represent the mean + standard 
deviation from triplicate samples of two independent experiments, expressed as a percent 
of neutral red uptake induced by the p33/p55 mixture.  These data suggest that p33/p55 
mixtures exhibit similar vacuolating activity in gastric cell lines.  C) Dilutions of the 
normalized E. coli soluble extracts containing the indicated proteins as in panle A were 
added to HeLa cells as described above.  Vacuolating activity was measured by a neutral 
red uptake assay.  Results represent the mean + standard deviation from triplicate 
samples, expressed as a percent of neutral red uptake induced by 10 µg/ml of full-length 
acid-activated VacA toxin purified from H. pylori culture supernatant. 
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The C-terminal region of p55 is important for maximum vacuolating  
cytotoxic activity 
 
 In an effort to map the minimal p55 protein capable of complementing the p33 
domain for vacuolating activity, we generated a series of p55 proteins truncated at the C-
terminus.  The truncated p55 proteins were expressed in E. coli (Fig. 14A) and then tested 
for their ability to exhibit vacuolating activity when mixed with the p33 VacA domain.  A 
p55 truncated protein containing amino acids 312-780 complemented the p33 domain, 
resulting in high levels of vacuolating activity (Fig. 14B).  In contrast, a p55-truncated 
protein containing amino acids 312-700 was impaired in its capacity to complement p33 
for vacuolating activity, and no detectable cytotoxic activity was observed when p55 
truncated proteins containing amino acids 312-550, or 312-478 were mixed with p33 
(Fig. 14B).  We also performed experiments designed to test the effect of these C-
terminal truncations on the activity of full-length recombinant VacA.  Similar to the 
results obtained with the truncated p55 proteins (Fig. 14B), a truncated VacA protein 
containing amino acids 1-780 exhibited extensive vacuolating activity, a VacA mutant 
protein containing amino acids 1-700 was impaired in its vacuolating activity, and a 
mutant protein containing amino acids 1-478 was completely inactive (Fig. 14C).  These 
data indicate that the p55 domain retains detectable functional activity when small 
segments of the C-terminus are deleted, but that activity is progressively lost with larger 
C-terminal deletions.   
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Figure 14.  Mapping the minimum portion of p55 required for vacuolating 
activity.  A) Plasmids encoding p33His, wild-type p55His (amino acids 312-821), and C-
terminal truncated versions of the p55His protein were transformed into the E. coli 
expression strain (JM109-DE3).  Proteins were expressed and soluble extracts containing 
the p55 proteins were generated as described in the Methods section.  Soluble proteins 
were electrophoresed on a 12% SDS-polyacrylamide gel, transferred to a nitrocellulose 
membrane and immunoblotted with an anti-His antibody (Santa Cruz).  B)  E. coli soluble 
extracts containing a mixture of p33 with p55-(312-821), p55-(312-780), p55-(312-700), 
p55-(312-550), or negative control (pET) were added to HeLa cells.  Normalized input 
proteins used in this experiment are shown in panel A.  Vacuolating activity was 
measured by a neutral red uptake assay and the results represent the mean + standard 
deviation from triplicate samples, expressed as a percent of neutral red uptake induced by 
p33/p55(312-821) samples.  C)  E. coli soluble extracts containing the full-length 
recombinant VacA (1-821), or the truncated VacA recombinant proteins (1-780, 1-700, 
and 312-821) were added to HeLa cells as described above.  Vacuolating activity was 
measured by a neutral red uptake assay.  Results represent the mean + standard deviation 
from triplicate samples, expressed as a percent of neutral red uptake induced by the 
recombinant 1-821 VacA protein.  
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p33 and p55 domains form oligomeric complexes
 We hypothesized that the ability of the p33 and p55 proteins to complement each 
other for vacuolating activity might require the formation of protein complexes 
comprised of these two proteins.  To test whether the VacA domains could physically 
interact, we prepared E. coli soluble extracts containing the p33 and p55 proteins tagged 
with His- and/or c-Myc-tags and then performed a series of immunoprecipitation 
experiments.  In these experiments, only p33/p55 interactions (Fig. 15A; lanes 4 and 7), 
but not p55/p55 (Fig. 15A; lane 5) or p33/p33 (Fig. 15A; lane 6) interactions were 
detected.  These data indicate that the recombinant p33 and p55 proteins are capable of 
interacting in solution to form p33/p55 protein-complexes. 
To determine whether the p33 and p55 domains form only simple binary 
complexes or also higher ordered complexes in solution, we mixed different tagged 
versions of the p33 and p55 domains (p33His, p55His, and p33Myc-His) and then 
immunoprecipitated the protein complexes using an anti-c-Myc antibody.  When samples 
containing the p33His, p55His, and p33Myc-His proteins were mixed, they formed 
protein complexes comprised of all three proteins (p33Myc-His, p33His and p55His; Fig. 
15B, lane 3).  The ability to form these p33Myc-His/p33His/p55His complexes was 
dependent on the p33/p55 interaction (Fig. 15B; lane 2), since p33His and p33Myc-His 
failed to interact when mixed in the absence of p55 (Fig. 15B; lane 1).  These data 
indicate that p33/p55 protein complex can potentially be composed of at least three 
independent subunits.  However, we were unable to detect the assembly of the p33 and 
p55 domains into large 1,000 kDa complexes similar to those formed by the 88 kDa 
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secreted VacA proteins present in H. pylori broth culture supernatant, based on analysis 
involving gel filtration chromatography (16).  
 
Interactions of p33 and p55 domains with full-length 88 kDa VacA
We next investigated whether the p33 and p55 proteins could form mixed 
oligomeric complexes with wild-type 88 kDa VacA protein purified from H. pylori 
culture supernatants.  To this end, E. coli soluble extracts containing p33, p55, or the 
p33/p55 mixture were mixed with a full-length 88 kDa c-Myc tagged VacA (Myc-VacA) 
purified from H. pylori supernatant and the proteins were then immunoprecipitated with 
an anti-c-Myc antibody as described above.  Interestingly, we were not able to detect 
mixed oligomer formation between the Myc-VacA and either the p33 or the p55 domains 
when these domains were tested independently (Fig. 15C).  In contrast, when the p33 and 
p55 domains were mixed together with the Myc-VacA, they formed mixed complexes 
composed of Myc-VacA, p33 and p55 (Fig. 15C).  These data provide evidence 
indicating that both the p33 and p55 domains play a role in the process of VacA assembly 
into oligomeric structures in solution.      
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Figure 15.  p33 and p55 interact in solution to form oligomeric complexes.  A) 
Epitope-tagged VacA domains were expressed as described in In the Methods section.  E. 
coli soluble extracts containing similar amounts of p33His, p33Myc-His, p55His, 
p55Myc alone or the indicated combinations were incubated with an anti-c-Myc antibody 
and proteins were immunoprecipitated (I.P.) as described in the Methods section.  
Immunoprecipitated proteins were electrophoresed on a 10% SDS-polyacrylamide gel, 
transferred to a nitrocellulose membrane, and immunobloted (I.B.) with an anti-His 
antibody (top panel) or anti-c-Myc antibody (bottom panel).  These data (lanes 4 and 7) 
suggest that p33 and p55 interact in solution to form heterotypic p33/p55 complexes.  B)  
E. coli soluble extracts containing similar amounts of the different p33 and p55 VacA 
proteins alone or the indicated combinations were incubated with an anti-c-Myc antibody 
and proteins were immunoprecipitated as described in panel A.  Immunoprecipitated 
proteins were electrophoresed on a 10% SDS-polyacrylamide gel, transferred to a 
nitrocellulose membrane, and immunobloted with an anti-His antibody.  These data 
suggest that p33 and p55 can interact in solution to form p33/p55 complexes that are 
composed of at least three independent VacA domains.  C) E. coli soluble extracts 
containing the indicated recombinant VacA proteins were mixed with acid-activated full-
length c-Myc-tagged VacA protein (Myc-VacA) purified from H. pylori culture 
supernatant (2 µg) as indicated.  Mixtures were then incubated with an anti-c-Myc 
antibody and proteins were immunoprecipitated as described in panel A.  
Immunoprecipitated proteins were electrophoresed on a 12% SDS-polyacrylamide gel, 
transferred to a nitrocellulose membrane and immunobloted with an anti-His antibody 
(top panels) or anti-c-Myc antibody (bottom panel).  These data suggest that the p33 and 
p55 domains can form mixed-oligomeric complexes with full-length 88 kDa VacA only 
when both domains are present. 
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The p33 and p55 VacA domains interact with mammalian cell membranes 
 
In the next series of experiments, we investigated the functional roles of the p33 
and p55 domains in the process whereby VacA interacts with mammalian cells.  As a first 
approach, interaction of the p33 and p55 domains with mammalian cells was investigated 
by immunoblot analysis.  When added individually to cells for 1 h at 4oC, both the p33 
and p55 domains were able to interact with the surface of HeLa cells (Fig. 16A).  
However, when the p33 and p55 domains were mixed and then added to HeLa cells, the 
amount of p33 and p55 protein associated with cells increased dramatically compared to 
the amount detected when these proteins were tested individually (Fig. 16A).   
As a second approach to investigate p33 and p55 interactions with mammalian 
cells, we used indirect immunofluorescence.  The interaction of p33 with the HeLa cell 
surface was detected using an anti-c-Myc antibody (Fig. 16B; panels 1-4) and the 
interaction of p55 with the HeLa cell surface was detected using an anti-VacA polyclonal 
antibody (Fig. 16B; panels 5-8).  As expected, full-length VacA (Myc-VacA) purified 
from H. pylori bound to the surface of HeLa cells (Fig. 16B; panels 1 and 5).  The p33 
(p33Myc-His) domain also bound to the surface of HeLa cells, but in contrast to the full-
length Myc-VacA, the p33 domain localized in a punctate distribution on the surface of 
HeLa cells (Fig. 16B; panel 3).  The punctate p33Myc-His distribution detected with the 
anti-Myc antibody was specific for this VacA protein, since no signal was detected when 
E. coli negative control lysate (pET) was used (Fig. 15B; panels 2 and 6).  As shown in 
Fig. 16B, we were able to detect binding of the p55 domains to the surface of cells by 
immunoblot methodology, but we were unable to detect interaction of the recombinant 
p55 protein with the surface of HeLa cells using immunofluorescence assays, despite 
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testing two different forms of this protein (p55His or p55Myc) and multiple antibodies, 
including the anti-VacA polyclonal used in panel A (Fig. 16B; panel 7).  We presume 
that the relevant epitopes are not accessible to the antibodies under the conditions of the 
immunofluorescence assay.  Interestingly, when E. coli soluble extracts containing the 
p33 and the p55 proteins were mixed and then added to HeLa cells, both proteins were 
detected on the surface of HeLa cells and were localized in a continuous pattern (non-
punctate), similar to full-length VacA (Fig. 16B; panels 4 and 8).  Thus, binding of p55 to 
the cell surface was detected by immunofluorescence assay if the p33 and p55 domains 
were added together to cells, but not if p55 was added independently to cells.  The p33 
distribution on the surface of HeLa cells was punctate when added alone to cells, whereas 
it was continuous (non-punctate) when p33 was added to cells together with the p55 
domain (Fig. 16B; panels 3 and 4).  In summary, these data indicate that the p33 and p55 
VacA domains can each independently interact with mammalian cell surfaces, but the 
binding interactions are substantially altered if the two domains are both present.  
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Figure 16.  Both p33 and p55 VacA domains interact with mammalian cells.  
A) E. coli soluble extracts containing similar amounts of the indicated VacA proteins 
were added to HeLa cells for 1h at 4oC.  The capacity of the VacA proteins to interact 
with host cell membranes was assessed by immunoblot (I.B.) analysis using an anti-VacA 
polyclonal antibody to detect p55His and anti-His antibody to detect p33Myc-His as 
described in the Methods section.  Both the p33 and p55 VacA proteins interacted with 
cells when added alone, but the binding of both proteins was enhanced when the p33/p55 
mixture was added to cells.  B) HeLa cells were intoxicated for 1h at 37oC with c-Myc-
VacA (Myc-VacA; 5 µg/ml) purified from H. pylori culture supernatant (panels 1 and 5), 
E. coli negative control lysate without VacA proteins (pET; panels 2 and 6), or with E. 
coli soluble extracts containing p33Myc-His (panel 3), p55His (panel 7), or with the 
p33Myc-His/p55His (panels 4 and 8) mixture.  The capacity of the VacA proteins to 
interact with the cell membrane of host cells was assessed by indirect 
immunofluorescence (I.F.) using anti-c-Myc to detect the p33Myc-His protein  (panels 1-
4) and anti-VacA polyclonal antibody to detect the p55 protein (panels 5-8) as described 
in the Methods section.   
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Intracellular localization of the p33 and p55 VacA domains
 Full-length 88 kDa VacA produced by H. pylori binds to the plasma membrane of 
cells and then can be internalized into target cells via an energy-dependent and 
temperature-dependent process (53).  Therefore, we next investigated whether the p33 
and p55 proteins were internalized into mammalian cells.  HeLa cells were intoxicated 
with either purified VacA from H. pylori, E. coli soluble extracts containing the p33 
domain, the p55 domain, or the p33/p55 mixture.  Internalized VacA proteins were 
visualized by indirect immunofluorescence analysis of permeabilized cells using an anti-
VacA monoclonal antibody (5E4) specific for the p55 domain (Fig. 17; panels 1, 3, and 
5) and an anti-c-Myc antibody to detect the p33Myc-His protein (Fig. 17; panels 2 and 4).  
Purified VacA was internalized into HeLa cells as shown previously (Fig. 17; panel 1).  
Even though the p33 and p55 domains bind to cells (Fig. 16), no internalization of the 
p33 or p55 proteins was detected when they were added alone to cells (Fig. 17; panels 2 
and 3).  In contrast, when the p33 and the p55 proteins were mixed and then added to 
cells, both domains were internalized and localized in a similar distribution as the full-
length VacA (Fig. 17; panels 4 and 5).  These data indicate that both the p33 and p55 
VacA domains are required for toxin internalization into target cells. 
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Figure 17.  The p33 and p55 VacA domains are required for 
toxin internalization into mammalian cells.  Wild-type VacA purified 
from H. pylori culture supernatant (panel 1), or E. coli soluble extracts 
containing similar amounts of p33Myc-His (panel 2), p55His (panel 3), or 
the p33Myc-His/p55His (panels 4 and 5) mixture were added to HeLa 
cells for 1.5 h at 37oC.  Then the media was replaced with fresh culture 
media and cells were incubated for an additional 16-24 h at 37oC as 
described in the Methods section.  The ability of VacA to enter into cells 
was assessed by indirect immunofluorescence (I.F.) of permeabilized cells 
using the 5E4 monoclonal anti-VacA antibody to detect the p55 protein 
(panels 1, 3, and 5) and the anti-c-Myc antibody to detect the p33Myc-His 
protein (panels 2 and 4), as described in the Methods section.  These data 
suggest that the p33 and p55 VacA domains are internalized into 
mammalian cells when both domains are present (panels 4 and 5), but not 
when added individually to cells. 
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Sequential addition of p55 and p33 VacA domains to cells induces cell vacuolation 
 
 To further investigate the role of p33 and p55 binding to host cells in the VacA 
intoxication process, we investigated whether the p33 and p55 domains could 
complement each other when added sequentially to HeLa cells.  To this end, we 
intoxicated HeLa cells sequentially with E. coli soluble extract containing p33 followed 
by extract containing p55 (p331, p55), or p55 first and then p33 (p551, p33).  The 
concentrations of p33 and p55 proteins in these experiments were approximately 
equivalent based on immunoblotting with an anti-His tag antibody.  In each case, the 
media overlying cells (containing unbound VacA) was washed away prior to the addition 
of the second VacA protein.  As shown above (Fig. 13), no vacuolating activity was 
observed when the pET, p33, or p55 lysates were added independently to cells, and 
extensive vacuolating activity was observed when the p33/p55 mixture was added to cells 
(Fig. 18A).  When the samples were added sequentially to cells, no vacuolating activity 
was detected if the p33 domain was bound first followed by the addition of the p55 
domain (Fig. 18A; p331, p55).  In contrast, extensive vacuolating activity was observed if 
the p55 domain was bound first followed by the addition of the p33 domain (Fig. 18A; 
p551, p33). 
To investigate why the (p551, p33) combination induced vacuolation but the 
(p331, p55) combination did not, we analyzed the interactions of sequentially added 
VacA proteins with the surface of host cells by immunoblot analysis.  As shown above, 
both the p33 and p55 domains were capable of binding to the plasma membrane of HeLa 
cells when added independently (Fig. 18B, lanes 1 and 2), and enhanced binding to cells 
of both domains was detected following simultaneous addition of the p33/p55 mixtures 
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(Fig. 18B; lane 3).  When the p55 domain was bound first followed by the p33 domain, a 
condition that resulted in cell vacuolation (p551, p33; Fig. 18A), the amount of p33 
protein bound to cell membranes increased compared to when the p33 domain was added 
alone (Fig. 18B; bottom panel lane 2 vs. 5).  Similarly, when the p33 domain was bound 
first followed by the p55 domain, a condition that failed to produce cell vacuolation 
(p331, p55; Fig. 18A), the amount of p55 protein bound to cell membranes increased 
compared to when the p55 domain was added alone (Fig. 18B; top panel lane 1 vs. 4).  
Similar results were obtained when different tagged p33 and p55 proteins (e.g. p33Myc-
His and p55Myc) and gastric cell lines (AGS and AZ-521) instead of HeLa cells were 
used.  These data suggest that binding of either p33 or p55 to cells enhances subsequent 
binding of p55 or p33, respectively.   
We then investigated the distribution of sequentially bound p33 and p55 proteins 
on the surfaces of host cells.  HeLa cells were intoxicated as described above and binding 
of the p33 and p55 proteins was detected by indirect immunofluorescence.  The 
interaction of p55 with the HeLa cell surface was detected using an anti-VacA polyclonal 
antibody (Fig. 19A) and the interaction of p33 (p33Myc-His) with the HeLa cell surface 
was detected using an anti-c-Myc antibody (Fig. 19A).  As shown above, when cells were 
intoxicated simultaneously with the p33/p55 mixture, both proteins interacted with the 
cells and localized in a continuous (non-punctate) pattern on the surfaces of cells (Fig. 
19A, panel 1).  Interestingly, when the p33 protein was added first followed by the p55 
protein (p33Myc-His1, p55His), both domains localized in a punctate distribution on the 
surface of the cells (Fig. 19A, panel 2).  Similarly, when the p55 protein was added first 
followed by the p33 protein (p55His1, p33Myc-His), both domains also localized in a 
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punctate distribution on the surface of the cells (Fig. 19A, panel 3).  Thus, when the p33 
and p55 VacA proteins are added sequentially to cells, both domains bind to the cell 
surface in a punctate distribution, and the pattern of binding is similar in the (p331, p55) 
and (p551, p33) experiments.  However, these data do not provide a clear explanation for 
why the (p551, p33) combination induces cellular vacuolation but the (p331, p55) 
combination does not.   
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Figure 18.  Sequential addition of p33 and p55 domains to HeLa cells.  A)  
HeLa cells were intoxicated for 1 h at 37oC with the indicated E. coli soluble extracts.  
Alternatively, HeLa cells were sequentially intoxicated first with E. coli soluble extract 
containing p33 and then p55 (p331, p55), or p55 first and then p33 (p551, p33).  In these 
sequential addition experiments the first sample (1) was incubated with cells for 1h at 
37oC, then unbound proteins were washed away and the second sample was added for an 
additional 1h at 37oC.  Input proteins were normalized by densitometry analysis of the 
immunoblot x-ray films, such that the relative concentrations of p33 and p55 domains 
were approximately equivalent.  Vacuolating activity was measured by a neutral red 
uptake assay.  Results represent the mean + standard deviation from triplicate samples.  
These results indicate that the p33 and p55 VacA domains can exhibit vacuolating 
activity when added sequentially to mammalian cells (p551, p33).  B)  E. coli soluble 
extracts containing p55His and p33Myc-His were added to HeLa cells as indicated for 1h 
at 37oC.  The capacity of the VacA proteins to interact with host cell membranes was 
assessed by immunoblot (I.B.) analysis using an anti-VacA polyclonal antibody to detect 
the p55 protein (top panel) and an anti-His antibody to detect the p33 protein (bottom 
panel).  C) HeLa cells were intoxicated for 1h at 37oC with E. coli soluble extract 
containing a p33/p55 mixture (row 1).  Alternatively, p33 was bound first followed by 
p55 (p331, p55; row 2), or p55 was bound first followed by p33 (p551, p33; row 3).  The 
capacity of the VacA proteins to interact with the cell membrane of host cells was 
assessed by indirect immunofluorescence (I.F.) using an anti-VacA polyclonal antibody 
to detect p55His (p55; left panels) and an anti-c-Myc antibody to detect the p33Myc-His 
protein (p33; right panels).    
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Internalization of sequentially added p33 and p55 VacA domains 
 
We hypothesized that the lack of vacuolating activity when the p33 domain is 
added first followed by the p55 domain (p331, p55) is due to the lack of VacA 
internalization.  To test this hypothesis, we analyzed the internalization of the p55 
domain.   As shown above (Fig. 17), no internalization of the p55 protein was detected 
when it was added alone to cells, but when the p55 and p33 proteins were mixed and 
added to cells, the p55 protein was internalized (p33/p55; Fig. 19).  Similarly, when the 
p55 domain was added first to cells followed by the p33 domain (p551, p33), a condition 
that results in cell vacuolation (Fig. 18A), internalized p55 protein was detected. (p551, 
p33; Fig. 19).  In contrast, when the p33 protein was added first followed by the p55 
protein (p331, p55), a condition that fails to cause call vacuolation (Fig. 18A), the p55 
protein was not detected inside cells (p331, p55; Fig. 19).  Similar results were obtained 
when p33 was detected.  These data indicate that in these sequential addition 
experiments, the order in which VacA domains are added to cells is an important 
determinant of whether VacA is internalized.   
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Figure 19.    Internalization of the p55 VacA domains.  A) HeLa 
cells were intoxicated for 1h at 37oC with E. coli soluble extract 
containing the indicated samples.  Then the media was replaced with fresh 
culture media and cells were incubated for an additional 16-24 h at 37oC.  
The ability of p55 to enter into cells was assessed by indirect I.F. of 
permeabilized cells using an anti-VacA polyclonal antibody to detect the 
p55 VacA domain.  These data suggest that the p55 VacA domain is 
internalized into mammalian cells when both domains are present or when 
p55 is added first, followed by p33 (p551,p33).  Sequential addition in the 
opposite order (p331,p55) did not lead to detectable VacA internalization. 
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Discussion 
 
The H. pylori VacA toxin has the ability to induce an array of structural and 
functional alterations in intoxicated mammalian cells (58, 70).   Previous studies have 
demonstrated that the mature secreted VacA toxin undergoes proteolytic degradation to 
yield two fragments (p33 and p55) (90, 94), but the relevant features of these two 
putative domains remain poorly characterized.  In the current study, we expressed 
recombinant p33 and p55 VacA proteins, and sought to characterize functional properties 
of these two putative domains.   
Our data indicate that the p33 and p55 VacA domains interact in solution to form 
protein complexes (Fig. 15A).  This finding is consistent with the results of previous 
studies, which demonstrated that p33 and p55 proteins interact in the yeast two-hybrid 
system (CHAPTER II) (94), as well as in HeLa cells transiently co-transfected with 
plasmids expressing p33 and p55 (111).  In addition, previous studies have shown that 
proteolysis of H. pylori VacA oligomeric complexes yields p33 and p55 fragments, 
which remain physically associated following proteolysis (CHAPTER II) (94).   Notably, 
in the current study, heterotypic interactions between p33 and p55 were detected, but 
homotypic interactions (either p33/p33 or p55/p55) were not detected (Fig. 14A).  This 
finding is consistent with the results obtained in a yeast two-hybrid system (CHAPTER 
II) (94).  Heterotypic interactions between p33 and p55 have also been detected within 
cells using fluorescence resonance energy transfer (FRET) microscopy (107) or 
immunprecipitation methods (111), but whether p33 and p55 form homotypic complexes 
was not tested in these studies.  Although homotypic interactions between p33 and p55 
domains have not been detected in either the yeast two-hybrid system or in the current 
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study, it remains possible that such interactions could occur in the context of a membrane 
environment or within certain forms of VacA oligomers.   
VacA 88 kDa monomers produced by H. pylori can assemble into large water-
soluble oligomeric structures comprised of 6 to 14 subunits (1, 16, 46).  Our data indicate 
that when mixed together, p33 and p55 domains form complexes composed of at least 
three independent subunits (Fig. 15B).  However, we were unable to demonstrate 
assembly of p33 and p55 domains into high molecular mass oligomeric complexes 
similar to those formed by H. pylori VacA 88 kDa monomers (p88) (16).  Moreover, 
when p33 and p55 proteins were mixed individually in solution with full-length p88 
VacA from H. pylori, we were not able to detect interactions of either the p33 or the p55 
domain with full-length p88 (Fig. 15C).  In contrast, when the p33/p55 mixture is 
combined with p88-VacA, p33/p55/p88-VacA mixed oligomeric structures are formed 
(Fig. 15C).  Collectively, these results suggest that formation of large VacA oligomeric 
structures proceeds more efficiently via interactions among p88-VacA monomers, rather 
than via interactions among isolated p33 and p55 domains.  
The current studies indicate that p33 and p55 VacA domains are each 
independently able to interact with the surface of HeLa cells (Fig. 16A).  Several 
previous studies have concluded that amino acid sequences in the p55 domain contribute 
to VacA binding to cells (32, 76, 101, 103), but potential interactions of the p33 domain 
with host cells have been analyzed in less detail.  VacA binding to cells has been shown 
to be inhibited by antiserum reactive toward the p55 fragment but is not inhibited by 
antiserum reactive toward the p33 fragment (32).  Also, inactive recombinant VacA 
proteins truncated at their C-terminus (p55 domain) have been shown to be impaired in 
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their ability to bind to mammalian cells (102).  Furthermore, a truncated form of VacA 
containing mainly the p55 domain was reported to bind to target cells in a manner similar 
to full-length VacA (76).  Interestingly, it has been shown previously that both the p55 
and p33 domains are each able to associate with artificial lipid membranes in the absence 
of protein receptors (57), suggesting that each of these domains could potentially interact 
with lipids on the surface of mammalian cells.  Whether p33 and p55 domains can each 
bind to the same component or different components on the surface of mammalian cells 
is not currently known. 
An important conclusion of the current study is that VacA interactions with the 
surface of cells are altered in several ways when both p33 and p55 domains are present, 
compared to when only a single domain is present (Fig. 16).  First, the total amount of 
VacA bound to cells increases substantially if both p33 and p55 are present (compared to 
only a single VacA domain) (Fig. 16A), and this increased binding is observed for both 
the p33 and p55 domain.  Second, when p55 is added to cells in the absence of p33, the 
binding of p55 is detectable in immunoblot assays but not immunofluorescence assays 
(Fig. 16B).  In contrast, if both p55 and p33 domains are added to cells, the binding of 
p55 is detectable in immunofluorescence assays (Fig. 16B).  This suggests that the 
conformation or localization of the p55 domain on the surface of cells may be altered in 
the presence of the p33 domain.  Finally, when added individually to cells, the p33 
domain localizes in a punctate distribution on the cell surface, but when added to cells 
along with p55, p33 localizes in a continuous (non-punctate) distribution on the cell 
surface (Fig. 16B).  The VacA interactions with the surface of cells that occur when both 
p33 and p55 domains are present are presumably relevant to subsequent localization of 
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VacA within the cell.  Specifically, we demonstrate that when added together, p33 and 
p55 are both internalized by host cells, whereas internalization is not detectable when p33 
or p55 domains are added independently to host cells.  The failure of p55 to be 
internalized when added independently to cells is consistent with a previous study in 
which it was shown that a p55 protein produced by H. pylori binds to the surface of host 
cells but is not internalized (76). 
Another important conclusion of the current study is that p33 and p55 VacA 
domains lack detectable vacuolating activity when added individually to cells, but when 
mixed, the p33 and p55 domains complement each other for vacuolating activity (Fig. 
13).  Previous studies have shown that the p33 and p55 domains each lack detectable 
vacuolating cytotoxic activity when expressed intracellularly in transiently transfected 
cells, but that intracellular co-expression of these two domains results in vacuolating 
cytotoxic activity (20, 111, 113).  The minimum portion of VacA capable of inducing 
vacuolating cytotoxic activity when expressed intracellularly comprises amino acids 1-
422 (p33 together with amino acids 313-422 derived from p55) (113).   Our current study 
indicates that the minimum portion of VacA capable of inducing vacuolating cytotoxic 
activity when added to the surface of cells is larger than that which is required when 
expressed intracellularly in transiently transfected cells (Fig. 14B).  Specifically, we show 
that a VacA protein containing amino acids 1-700 possesses low levels of vacuolating 
cytotoxic activity when added to the surface of cells, and that further C-terminal 
truncations result in forms of VacA that have minimal or no detectable cytotoxic activity 
(Fig. 14C).  The requirement of a larger portion of p55 for vacuolating activity when 
VacA is added to the surface of cells compared to when VacA is expressed intracellularly 
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suggests that certain VacA amino acid sequences in this region (amino acids 422 to 821) 
may play an important role in the processes of VacA binding, internalization, or 
intracellular trafficking.  
Further insight into the role of p33 and p55 domains comes from studies in which 
these domains are added sequentially to cells (Fig. 18 and 19).  Binding of p55 to the cell 
surface followed by addition of p33 results in cell vacuolation, whereas addition of these 
domains in the opposite order fails to induce detectable cell vacuolation (Fig. 18A).  
There are numerous potential explanations for this result, but we favor a model in which 
p55 initially binds to a cell surface receptor, and subsequent addition of p33 leads to the 
formation of p55/p33 complexes, which are internalized by cells and produce vacuolating 
cytotoxic effects.  The experimental results presented here provide evidence suggesting 
that binding of VacA to the surface of cells via the p55 domain can lead to internalization 
of the toxin and vacuolating cytotoxic effects, whereas binding via the p33 domain is not 
an effective mechanism for toxin internalization and does not produce detectable 
vacuolating cytotoxic effects (Fig. 18 and 19).  We speculate that the p33 domain may 
bind to cell surface components that are different from those bound by p55, and that the 
cell surface component bound by p33 might not support internalization of the p33/p55 
complexes (Fig. 19).  Alternatively, this order of addition (p331,p55) may not permit the 
formation of the p33/p55 complexes in the proper conformation required for 
internalization.   
VacA causes numerous effects on intoxicated cells, and many effects of VacA are 
dependent on the capacity of VacA to form membrane channels (17, 100, 106).  
Therefore, it is of interest to view the current results in the context of what is known 
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about functional domains of other pore-forming toxins.  To our knowledge, VacA is the 
only pore-forming toxin that can be divided into two functional domains that complement 
each other for toxic activity when expressed individually.  Two previous studies have 
investigated putative functional domains of the pore-forming toxins aerolysin (23) and 
listeriolysin (LLO) (24).  In contrast to what is reported here with VacA, expression of 
separate domains of aerolysin and LLO, resulted in the production of proteins that lacked 
ability to complement each other for cytotoxic activity (23, 24).  Interestingly, when these 
domains were co-expressed inside the bacteria, in both cases, the two domains were able 
to assemble into cytotoxic proteins, suggesting that assembly of functional toxins might 
require interactions between the two domains during early stages of the protein folding 
process (23, 24).  The demonstration that VacA functional domains can complement each 
other for cytotoxic activity in solution suggests that there may be differences in the 
structural organization of VacA compared to most other known pore-forming toxins.  
Most pore-forming bacterial toxins act primarily on the plasma membrane of host cells, 
whereas VacA produces several effects that are dependent on its localization in 
intracellular sites.  It seems likely that the unique feature of VacA may be related to the 
capacity of this toxin to exert multiple activities in multiple cellular sites. 
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Figure 20.  Model of VacA interaction with mammalian cells.  Based on the 
data presented in this study, we propose a model in which VacA binds to mammalian 
cells via its p33 and p55 domains.  Even though both domains can bind to cell surfaces, 
our data suggest that VacA binding via the p55 domain is important for VacA 
internalization and cytotoxic activity.  We hypothesize that the VacA p55 domain binds 
to a receptor that is involved in the internalization of the surface-bound toxin.  Previously 
it has been shown that lipid rafts play a role in the internalization of VacA.  We 
hypothesize that binding of VacA via the p55 domain to lipid rafts or proteins within 
lipid rafts is required for the internalization of VacA channels, which in turns results in 
cell vacuolation.  
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CHAPTER IV 
 
INHIBITION OF PRIMARY HUMAN T CELL PROLIFERATION BY 
HELICOBACTER PYLORI     VACA TOXIN  
 
 
Introduction 
 
H. pylori can persistently colonize the human gastric mucosa for decades despite 
the development of gastric mucosal inflammation, infiltration of immune cells to the 
infection site, and specific antibody production.  CD4+ T cells have been shown to play a 
critical role in protection against H. pylori infection (2, 22, 41, 45).  Thus, it seems 
possible that H. pylori may have evolved mechanisms to inhibit or modulate T cell 
immunity.  Indeed, recently it has been demonstrated that CagA (i.e. a protein that is 
translocated into mammalian cells by the H. pylori type IV secretion system) and VacA 
are able to modulate the immune system (12, 34, 56, 95).  CagA has been shown to 
inhibit the proliferation of interleukin-dependent B cells by suppressing JAK-STAT 
signaling (95).  VacA has also been shown to modulate the immune response by 
inhibiting the activation of Jurkat T cells (a human T cell lymphoma/leukemia cell line) 
as well as human peripheral blood lymphocytes (PBL), and to inhibit class II antigen 
presentation (12, 34, 56).  Studies in Jurkat T cells indicate that VacA blocks activation 
of the nuclear factor of activated T cells (NFAT), a key transcription factor required for 
optimal T cell activation (34).  The process by which VacA inhibits NFAT activation in 
Jurkat T cells is reportedly similar to the actions of the immunosuppressive drugs 
cyclosporine A and FK-506, which inactivate the NFAT phosphatase calcineurin (34).  
However, whether VacA inhibits the activation of primary human CD4+ T cells has not 
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yet been studied in any detail.  This chapter describes studies in which VacA effects on 
primary human CD4+ T cells were investigated.   
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Methods 
 
Purification of VacA:  H. pylori strains (wild-type strain 60190 and isogenic 
mutant strains) were grown as described before (16, 52, 100).  Oligomeric forms of VacA 
were purified from broth culture supernatants of H. pylori as described previously (16).  
All experiments were performed using acid-activated preparations of VacA or acidified 
buffer control (PBS) (21), unless stated otherwise.  The final VacA concentration was 10 
µg/ml for all experiments, unless stated otherwise.  For the dominant-negative assays 
(100), wild-type VacA was mixed with varying concentrations of VacA mutant toxins 
and the mixtures were acid-activated prior to addition of these samples to cells.   
 
Primary human T cell purification and CFSE labeling:  Resting CD4+ human T 
cells were purified from healthy adult donors using magnetic bead purification (64, 96).  
The purified cells were 99% CD3+CD4+ as assessed by staining and flow cytometric 
analysis.  Cell proliferation was monitored by labeling T cells with carboxy fluorescein 
diacetate succinimide ester (CFSE; Molecular Probes) prior to stimulation with α-
CD3/α-CD28 antibodies.  Purified cells were washed and resuspended in PBS.  CFSE 
was added at a final concentration of 5 µM and incubated at 37°C for 3 min.  Labeling 
was quenched by addition of 50% fetal calf serum in PBS, followed by three washes with 
RPMI-supplemented media.  All CFSE labeling and cultures were performed in the dark.  
 
Activation of primary human T cells:  Purified resting T cells were activated by 
cross-linking with plate-bound anti-CD3 antibody (OKT-3, ATCC) and soluble anti-
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CD28 antibody (BD Biosciences).  The plates were first coated with anti-mouse IgG (10 
µg/ml, Caltag), followed by anti-CD3 antibody.  Cells were removed from the activation 
signals after 48 hours and expanded in media supplemented with recombinant human IL-
2 (Chiron, 200 U/ml).  Jurkat T cells were TCR/CD28-stimulated as described above, or 
with phorbol myristate acetate (PMA, 50 ng/ml; Sigma) and ionomycin (500 ng/ml; 
Sigma), and maintained in RPMI media containing 10% FCS.  To inhibit TCR/CD28 
stimulation or IL-2-driven stimulation, T cells were treated with cyclosporine A (50 nM, 
Alexis Biochemicals), FK506 (100 nM, Alexis Biochemicals), or rapamycin (200 ng/ml, 
Alexis Biochemicals) respectively.  
 
FACS Analysis and IL-2 detection:  IL-2 receptor (CD25) surface expression was 
detected by staining with phycoerythrin (PE)-conjugated anti-human CD25 (BD 
Biosciences).  Stained and CFSE-labeled cells were fixed with 1% paraformaldehyde and 
the data was acquired on a FACSCalibur flow cytometer and analyzed using the 
Cellquest software (BD Biosciences).  Forward- and side-scatter profiles were used to 
define the live population.  IL-2 secretion into culture supernatants was determined using 
cytometric bead array (CBA) according to the manufacturer’s instructions (BD 
Biosciences), and analyzed using CBA 6-bead analysis software (BD Biosciences).  
Samples were analyzed on a FACSCalibur® four color cytometer, using the CellQuest 
program.     
 
Generation and use of NFAT reporter primary human T cells:  To generate a 
primary human CD4+ T cell line that expressed an NFAT transcriptional reporter, three 
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tandem copies of the NFAT binding site of the IL-2 promoter (29) were sub-cloned 
upstream of the EGFP gene (Clontech) to direct its transcription (64).  This NFAT-GFP 
expression cassette was then cloned into a lentiviral vector in reverse orientation and 
VSV-G pseudotyped viruses were generated via co-transfection of 293 T cells (64).  
Activated primary CD4+ T cells were transduced with these pseudotyped viruses at a 
suboptimal MOI.  After 7 days, cells constitutively expressing GFP were removed by 
FACS sorting and GFP-negative cells were TCR/CD28- or PMA/Ionomycin-stimulated 
for 24 hours.  NFAT-GFP T cells that up-regulated GFP upon activation were positively 
sorted by flow cytometry and further expanded in IL-2-supplemented media.  Following 
enrichment, at least 10% of the NFAT-GFP T cell population displayed GFP-inducible 
expression upon TCR stimulation. 
 
Cell cycle analysis of T cell proliferation:  Day 4 TCR/CD28-stimulated T cells 
were washed to remove exogenous IL-2 and maintained in IL-2 free medium for 24 hours 
to synchronize cells at phase G1 of the cell cycle.  During this period, the cells were 
treated with VacA or other additives.  Following incubation in IL-2-containing medium 
for the indicated times, cells were subjected to propidium iodide (PI) staining and 
analyzed by flow cytometry (73).  To evaluate the kinetics of DNA replication, T cells 
were washed to remove IL-2, and treated with VacA for 8 hours.   Following VacA 
treatment, cells were incubated for 24 hours in IL-2-containing medium.  Then 10µM 5-
bromo-2-deoxyuridine (BrdU) was added to the cultures, and cells were harvested at 
different time points for BrdU antibody staining with a commercially available kit (BD 
Biosciences), according to the manufacturer’s instructions. 
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Results 
 
VacA inhibits activation-induced proliferation of primary  
human CD4+ T cells 
 
Previous reports have indicated that VacA inhibits activation of T cells, 
particularly a transformed T cell line (Jurkat T cells) (12, 34).  While several experiments 
were performed on peripheral blood lymphocytes (PBL) (34), the mode of VacA action 
on purified primary T cells was not assessed.  To investigate whether VacA inhibits the 
activation of primary T cells in a manner similar to its effect on transformed cells, we 
purified CD4+ primary human T helper (Th) cells from peripheral blood mononuclear 
cells (PBMC) of healthy individuals and labeled them with CFSE, a cell-permeable dye 
that allows for the quantification of cell division within a population.  CFSE-labeled Th 
cells were then pre-treated with medium, PBS, or VacA, followed by TCR and CD28 
stimulation using α-CD3 and α-CD28 antibodies (TCR/CD28 stimulation) as described 
in the Methods section.  As expected, Th cells pre-treated with medium or PBS rapidly 
proliferated, resulting in up to 7 divisions when analyzed at 5 days-post TCR/CD28 
stimulation (Fig. 21A and B).  In contrast, treatment with VacA potently inhibited the 
proliferation of Th cells (Fig. 21A and B) in a dose-dependent manner (Fig. 21C).  
Incubation of purified VacA at acid pH (pH <4.5; a process termed acid-activation) 
markedly enhances the capacity of the toxin to undergo internalization and cause 
vacuolating cytotoxic effects in mammalian cells (21, 53).  Accordingly, acid-activation 
markedly enhanced the capacity of VacA to inhibit Th cell proliferation (Fig. 21D). 
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Figure 21.  VacA inhibits activation-induced proliferation of primary human 
CD4+ Th cells.  A) purified primary human Th cells were labeled with CFSE and treated 
with acid-activated VacA (10 µg/ml), acidified-PBS (PBS), or medium alone for 1 hour, 
followed by TCR/CD28 stimulation for 48 hours as described in the Methods section.  
Control cells were treated with medium alone, without TCR/CD28 stimulation. Activated 
T cells were expanded in IL-2-containing media and T cell proliferation was analyzed at 
day 5 post-activation by flow cytometry.  B) graphic representation of the histograms 
shown in panel A.  C) dose-response analysis of VacA effects on primary human CD4+ T 
cell proliferation.  Th cells were CFSE-labeled and treated with different concentrations 
of acid-activated (pH 3) VacA for 1 hour.  Cells were then stimulated and analyzed as in 
panel A.  D) effects of acid-activated VacA (pH 3) and non-acid-activated VacA (pH 7.5) 
on T cell proliferation.  Th cells were CFSE-labeled and treated with acid-activated or 
non-activated VacA (10 µg/ml) as described above.  All the results are representative of 
three experiments using cells from different donors and different toxin preparations.   
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The N-terminal hydrophobic domain of VacA is required for inhibition of 
primary human Th cell proliferation 
 
Most of VacA effects on mammalian cells have been shown to be dependent of 
the ability of VacA to form membrane-channels (17, 100, 106).  Structure-function 
analyses have revealed that an intact structure of a hydrophobic domain within the VacA 
amino-terminal region is required for the formation of anion-selective membrane 
channels (Table 1) (52, 100).  We hypothesized that the formation of VacA anion-
selective channels may play an important role in the process by which VacA inhibits 
proliferation of activated T cells.  To further test this hypothesis, we examined the effects 
of three VacA mutant toxins, two of them contain single amino acid substitutions in the 
hydrophobic domain and one contains an in-frame deletion of the hydrophobic domain of 
VacA  (VacA-P9A, VacA-G14A, and VacA-∆{6-27} respectively) on proliferation of 
primary human Th cells (Table 1).  These VacA mutant proteins are defective in channel-
forming activity, but retain other structural and functional characteristics of the wild-type 
VacA protein, including the ability to form oligomeric structures and the capacity to bind 
and enter cells (Table 1) (52, 100, 106).  In contrast to wild-type VacA, these mutant 
proteins did not cause any detectable inhibition of T cell proliferation (Fig. 22).  These 
data indicate that an intact VacA amino-terminal hydrophobic domain is required for 
VacA-mediated inhibition of T cell proliferation, and suggest that the formation of VacA 
anion-selective membrane channels is important for the suppression of activation-induced 
proliferation of primary Th cells. 
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Table 1.  Characterization of VacA mutant toxins used in this study. 
VacA 
Toxins  
Oligomer 
formation a
Binding / 
internalization b
Channel 
formation c
Cytotoxic 
Activity d
WT e + + + + 
∆6-27 + + - - 
P9A + + - - 
G14A + + - - 
a Oligomer formation of VacA toxins was analyzed by determining whether these 
proteins eluted as large oligomeric structures (~1,000 kDa) from a gel-filtration 
chromatography column (16, 52, 100). 
b Binding and internalization of VacA toxins was assessed by indirect 
immunofluorescence analysis using HeLa cells (106). 
c VacA channel activity was assessed using planar lipid bilayers (52, 100).  
d Toxins (20 µg/ml) that induced vacuolation in more than 50% of HeLa cells were 
scored positive for cytotoxic activity (52, 100). 
e WT, wild-type VacA from H. pylori strain 60190. 
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Figure 22.  Analysis of VacA mutant proteins demonstrates 
that an intact N-terminal hydrophobic domain is required for VacA-
mediated effects on T cell proliferation.  Purified primary human Th 
cells were CFSE-labeled and treated with wild-type VacA (WT VacA, 10 
µg/ml), one of 3 different mutant toxins (each 10 µg/ml), or PBS for 1 
hour.  Cells were then TCR/CD28 stimulated for 48 hours, expanded in 
IL-2-containing media, and analyzed by flow cytometry at day 5 after 
stimulation as described in the Methods section.  Results are 
representative of three experiments using cells from different donors and 
different toxin preparations.   
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Effects of VacA on IL-2 secretion in Jurkat T cells and primary human 
T cells 
 
It has been reported recently that VacA blocks the secretion of interleukin-2 (IL-
2) by mitogen-stimulated Jurkat T cells (34). Therefore, we investigated whether VacA 
also inhibits IL-2 secretion in primary Th cells.  In agreement with a previous report (34), 
we found that wild-type VacA potently suppressed IL-2 secretion in Jurkat T cells, very 
similar to the immunosuppressive drugs cyclosporine A and FK506, regardless whether 
the cells were TCR/CD28-stimulated or stimulated with PMA and ionomycin (Fig. 23A).  
Notably, a VacA mutant toxin deficient in vacuolating cytotoxic activity and defective in 
its ability to inhibit primary Th cells proliferation (Fig. 22; VacA ∆6-27) did not inhibit 
IL-2 secretion in Jurkat T cells (Fig. 23A).  In contrast to the marked inhibitory effect of 
wild-type VacA on IL-2 secretion by Jurkat T cells, VacA had only a modest effect on 
IL-2 secretion by primary human Th cells (Fig. 23A).  To investigate if VacA might 
selectively inhibit IL-2 secretion in naïve or memory T cell subsets, we compared levels 
of IL-2 secreted by FACS-sorted naïve (CD45RA+/CD45RO-) and memory (CD45RA-
/CD45RO+) CD4+ T cells following treatment with VacA and TCR/CD28-stimulation.  
VacA treatment resulted in no detectable reduction of IL-2 secretion by either naïve or 
memory T cell subsets, whereas cyclosporine A treatment effectively inhibited IL-2 
secretion by both CD4+ subsets (Fig. 23B).  TCR/CD28 stimulation of primary human T 
cells induces the expression of both IL-2 and the high affinity IL-2 receptor α-chain 
(CD25).  Therefore, we next investigated whether VacA treatment inhibited the surface-
expression of CD25.  Primary human Th cells were pre-treated as described above and 
CD25 expression was analyzed at 24 h post-TCR/CD28 stimulation by flow cytometric 
analysis.  No significant difference was detected in the CD25 expression of VacA-treated 
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primary human T cells and cells treated with PBS or medium (Fig. 23C).  These data 
suggest that VacA-mediated inhibition of activation-induced proliferation of primary 
human CD4+ T cells is not due to effects on IL-2 secretion or cell surface expression of 
CD25. 
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Figure 23.  VacA-treated Jurkat T cells secrete diminished levels of IL-2, 
whereas VacA-treated primary human T cells continue to secrete high levels of IL-2.  
A) purified primary human Th cells (right columns) or Jurkat T cells (left columns) were 
pre-treated with medium alone, wild-type (WT) VacA, VacA-∆(6-27), or cyclosporine A 
(CspA) for 1 hour, followed by  TCR/CD28 stimulation (CD3/CD28; top panels) or 
stimulation with PMA (50 ng/ml) and ionomycin (500 ng/ml) (bottom panels), as 
indicated.  IL-2 secretion was measured at 24 h after stimulation using a cytometric bead 
array (CBA) as described in the Methods section.  Results represent the mean + S.D. 
from triplicate samples.  B)  Purified primary human Th cells were FACS-sorted into 
naïve (CD45RA+/CD45RO-) and memory (CD45RA-/CD45RO+) CD4+ T cell subsets.  
Purified cells were pre-treated as indicated for 1 hour, followed by TCR/CD28 
stimulation (CD3/CD28).  IL-2 secretion was as described in panel A.  Results represent 
the mean + S.D. from duplicate samples from two different donors, and are expressed as 
the percentage of IL-2 secreted by the control cells pre-treated with medium.  C) Purified 
primary human Th cells were pre-treated as indicated, followed by TCR/CD28 
stimulation (CD3/CD28).  IL-2 receptor α-chain (CD25) surface expression was detected 
24 h after stimulation by staining with phycoerythrin (PE)-conjugated anti-human CD25 
(BD Biosciences).  Results are expressed as the percentage of surface expressed CD25 in 
control cells pre-treated with medium. 
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VacA inhibits primary human T cell proliferation through an NFAT-
independent mechanism 
 
To further confirm that the lack of proliferation of VacA-treated primary Th cells 
was not due to insufficient IL-2 levels in the medium, the cultures were supplemented 
with saturating concentrations of exogenous recombinant IL-2 (200 U/ml) during 
TCR/CD28 stimulation.  VacA potently inhibited the proliferation of primary Th cells, 
even in the presence of excess exogenous IL-2 (Fig. 24A).  Thus, together with data 
presented in figure 20, we conclude that the VacA-mediated inhibition of primary human 
Th cell proliferation cannot be attributed to VacA effects on IL-2 secretion.   
VacA has been shown to inhibit NFAT activation in Jurkat T cells, resulting in a 
loss of IL-2 secretion (34).  However, since VacA has only a modest effect on IL-2 
secretion and CD25 surface-expression in primary T cells (Fig 23B and C), we 
hypothesized that VacA-mediated inhibition of primary human T cell proliferation may 
occur via an NFAT-independent mechanism.  To test this hypothesis, we developed a 
primary human Th cell stably transduced with a lentiviral vector in which the NFAT 
binding site of the IL-2 promoter drives the expression of the green fluorescent protein 
(NFAT-GFP T cells) (64).  NFAT-GFP T cells were treated with wild-type VacA, PBS, 
cyclosporine A, or VacA-∆(6-27) for 1 hour prior to TCR/CD28 stimulation.  GFP 
expression was then analyzed 24 hours-post stimulation via flow cytometric analysis.  As 
expected, GFP expression was induced upon TCR/CD28 stimulation of NFAT-GFP T 
cells (Fig. 24B).  In the presence of cyclosporine A, which is potent inhibitor of NFAT 
activation, stimulated NFAT-GFP T cells did not express GFP (Fig. 24B).  Stimulated 
cells treated with VacA expressed GFP similar to the PBS-treated cells, regardless 
whether the primary cells were TCR/CD28-stimulated or stimulated with 
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PMA/ionomycin (Fig. 24B). These results, taken together with our findings that VacA 
causes only modest effects on IL-2 secretion in primary Th cells, suggest that VacA can 
inhibit proliferation of primary human Th cells via an NFAT-independent mechanism. 
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Figure 24.  VacA inhibits activation-induced proliferation of 
primary human Th cells independent of effects on IL-2 secretion and 
NFAT activation.  A) purified primary human Th cells were CFSE-
labeled and pre-treated with wild-type VacA or PBS in the presence or 
absence of supplemental IL-2 (200 U/ml) for 1 hour as indicated.  Cells 
were then TCR/CD28 stimulated in the presence or absence of 
supplemental IL-2 for 48 h, expanded in IL-2 supplemented media, and 
subjected to flow cytometric analysis at day 5 post-treatment.  B) primary 
human CD4+ T cells stably transduced with a GFP reporter under the 
control of NFAT (NFAT-GFP Th cells; see Methods section) were pre-
treated with the different additives as in panel  A for 1 hour prior to 
TCR/CD28 stimulation (CD3/CD28).  GFP expression was assessed by 
flow cytometric analysis 24 hours after stimulation.  Results represent the 
mean + S.D. from triplicate samples and are expressed as the percentage 
of cells demonstrating inducible expression of GFP, relative to the PBS-
treated cells.  CspA, cyclosporine A (50 nM); WT, wild-type VacA toxin 
(10 µg/ml); and ∆6-27, VacA-∆(6-27) mutant toxin (10 µg/ml).   
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VacA inhibits IL-2-driven proliferation of primary human Th cells, but not 
IL-2-dependent survival 
 
 To gain further insight into the mechanism employed by VacA to suppress 
activation-induced proliferation of primary T cells, we investigated the kinetics of VacA-
mediated effects.  CFSE-labeled primary human Th cells were TCR/CD28-stimulated as 
previously described, and treated with PBS, wild-type VacA, or VacA-∆(6-27) at 
different time points after stimulation.  T cell proliferation was assessed 5 days after 
stimulation by flow cytometric analysis.  VacA inhibited proliferation of Th cells even 
when added 48 hours after stimulation, suggesting that VacA effects are largely 
independent of early TCR/CD28 signals (Fig. 25A).   
We next tested whether VacA blocked IL-2-dependent proliferation of primary T 
cells at later time points (96 hours) after stimulation, a stage in which T cell proliferation 
and survival are solely dependent on IL-2 signals, but not on TCR/CD28 signals (27).  
For these experiments, Th cells were TCR/CD28-stimulated for 48 hours and expanded in 
the presence of IL-2 for an additional 2 days.  At day 4 post-activation, T cells were 
removed from IL-2, and treated with VacA or other additives for 24 hours.  IL-2 was then 
added back to the medium and cells were expanded for an additional 3 days.  Cell counts 
were performed to assess cellular proliferation at day 3 post-IL-2 stimulation.  As 
expected, activated T cells treated with PBS and stimulated with IL-2 proliferated 
approximately 6-fold from day 0 to day 3, and no proliferation was observed in the 
absence of IL-2 (Fig. 25B).  In the presence of VacA, however, T cell numbers only 
increased about 3-fold (p < 0.001), similar to cells treated with rapamycin, an 
immunosuppressive drug that blocks IL-2 driven proliferation of T cells (Fig. 25B) (14, 
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75).  These data indicate that VacA inhibits IL-2-driven proliferation of activated primary 
human Th cells. 
IL-2 signals are required not only for activation-induced T cell proliferation, but 
also for survival of these cells (27).  Therefore, we also monitored the viability of the 
activated Th cells cultured in the presence or absence of VacA.  As expected, the majority 
of activated T cells (>90%) incubated without IL-2 for 3 days underwent apoptosis (Fig. 
25C).  In contrast, VacA treatment did not result in a significant increase in cell death 
(Fig. 25C), suggesting that VacA inhibits IL-2-driven proliferation without altering IL-2-
dependent survival.   
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Figure 25.  VacA inhibits IL-2-driven proliferation of primary human Th 
cells.  A) wild-type (WT) VacA (10 µg/ml) or VacA-∆(6-27) (10 µg/ml) were added to 
CFSE-labeled purified primary human CD4+ T cells at the indicated time points either 
preceding or following (pre or post) TCR/CD28 stimulation.  Activated cells were 
expanded in IL-2-containing media and cell proliferation was analyzed by flow 
cytometry at day 5 after stimulation.  B) primary human Th cells were TCR/CD28 
stimulated for 48 hours and expanded in the presence of IL-2 for 2 additional days.  At 
day 4 after stimulation, T cells were removed from IL-2 and treated with PBS, wild-type 
VacA (10 µg/ml), or rapamycin (Rap; 200 ng/ml) for 24 hours.  After 24 hours, IL-2 was 
added back to the media as indicated and cells were treated again with the different 
additives and expanded in fresh media containing supplemental IL-2 for 3 days.  Cell 
proliferation was assessed by cell counting with a hemacytometer.  Results represent the 
mean + S.D. from triplicate samples.  * = p < 0.001 when compared to the PBS-treated 
cells.  C) viability of Th cells was determined by flow cytometric gating for viable cells 
based on forward and side scatter properties at day 1, 2, and 3 after TCR/CD28 
stimulation.  
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VacA attenuates IL-2-dependent cell cycle progression in primary 
human Th cells 
 
To determine whether VacA-mediated inhibition of IL-2-driven proliferation is 
due to a perturbation of cell cycle progression, we assessed cell cycle progression of 
activated T cells in the presence of VacA.  Primary human Th cells were TCR/CD28-
stimulated and expanded in IL-2-containing medium as described above.  Day 4-activated 
Th cells were removed from IL-2 for 24 hours to induce a G1-phase cell-cycle arrest (62), 
and were then treated with VacA or other additives.  IL-2 was then added back to the 
medium, and cell cycle distribution was analyzed at different time points through 
propidium iodide (PI) staining.  The activated Th cells arrested in G1-phase re-entered the 
cell cycle approximately 24 to 36 hours after IL-2 stimulation, as seen by the increased 
number of Th cells in S and G2M phases (Fig. 26).  In contrast, cells treated with either 
rapamycin (which inhibits IL-2-induced cell cycle progression by arresting the cells at the 
G1-phase) (14, 62, 75)or VacA displayed impaired IL-2-induced cell cycle progression 
(Fig. 26).  Taken together, these data provide strong evidence that VacA inhibits IL-2-
driven proliferation in activated primary human Th cells by suppressing cell cycle 
progression. 
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Figure 26.  VacA delays IL-2-driven cell cycle progression.  A) 
Propidium iodide (PI) staining Histograms of primary human Th cells.  
Primary human Th cells were TCR/CD28 stimulated for 48 hours and 
expanded in the presence of IL-2 for 2 additional days.  At day 4 after 
stimulation, T cells were removed from IL-2 and treated with PBS, wild-type 
VacA (10 µg/ml), or rapamycin (Rap; 200 ng/ml) for 24 hours.  After 24 
hours, IL-2 was added back to the media as indicated and cells were treated 
again with the different additives and expanded in fresh media containing 
supplemental IL-2 for 3 days.  Cell-cycle distribution was analyzed at 12, 24, 
and 36 h following IL-2 stimulation using and flow cytometry analysis.  B) 
The percentages of total cells in S-phase and G2M phase 36 h post IL-2 
stimulation are shown.  Results represent the mean + S.D. from triplicate 
samples.  * = p < 0.01 when compared to the PBS treated cells.  Results are 
representative of at least two experiments using cells from different donors 
and different toxin preparations.   
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VacA-∆(6-27) inhibits the immunosuppressive effects of wild-type VacA  
on T cells 
 
In studies of VacA-induced effects on HeLa cells and AGS cells (a human gastric 
epithelial cell line), the VacA mutant toxin (VacA-∆6-27) has been reported to exhibit a 
dominant-negative phenotype (100).  When mixed in an equimolar ratio with wild-type 
VacA, VacA-∆(6-27) blocks the capacity of wild-type VacA to cause cell vacuolation 
(100), form anion-selective membrane channels (100), induce cytochrome c release 
(106), and induce apoptosis (17).  The inhibitory actions of VacA-∆(6-27) are thought to 
be due to the formation of inactive mixed-oligomeric complexes, comprised of both wild-
type and mutant toxin (100).  To investigate whether VacA-∆(6-27) could block the 
actions of wild-type VacA on Th cells, the two toxins were mixed and added at various 
stoichiometric ratios to CFSE-labeled, resting Th cells.  CFSE-labeled primary human Th 
cells were subsequently TCR/CD28 stimulated, and proliferation was evaluated by flow 
cytometric analysis 5 days post-stimulation.  VacA-∆(6-27) potently blocked wild-type 
VacA-mediated inhibition of T cell proliferation in a dominant-negative fashion, since it 
was partially effective even in the presence of 20-fold molar excess of wild-type VacA 
(Fig. 27A). VacA-∆(6-27) also blocked the inhibitory effects of wild-type VacA on IL-2 
secretion in Jurkat T cells (Fig. 27B), suggesting that the VacA-∆(6-27) is able to block 
VacA effects on T cells.  
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Figure 27.  Effects of a dominant-negative mutant VacA toxin.  
Α) primary human Th cells were CFSE-labeled and then treated for 1 h 
with wild-type VacA and VacA-∆(6-27) in different ratios (WT:∆6-27) as 
indicated.  Cells were then TCR/CD28 stimulated and expanded in IL-2-
supplemented media.  Cell proliferation was analyzed by flow cytometric 
analysis on day 5 after stimulation.  B) Jurkat T cells were pre-treated with 
wild-type VacA and VacA-∆(6-27) as in panel A for 1 h as indicated, 
activated with PMA and ionomycin, and then incubated for 24 h.  Culture 
supernatants were assayed for IL-2 secretion using a cytometric bead array 
(CBA) assay as described in the Methods section.  Results are 
representative of three experiments using cells from different donors, 
different preparations of Jurkat T cell lines, and different toxin 
preparations. 
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Discussion 
 
 
In this study we show that VacA inhibits the proliferation of TCR/CD28-
stimulated primary human CD4+ T helper (Th) cells (Fig. 18).  In addition, our data 
demonstrate a qualitative difference between VacA-mediated effects on IL-2 secretion by 
Jurkat T cells and primary human Th cells (Fig. 20).  In contrast to the potent inhibitory 
effects of VacA on IL-2 secretion in Jurkat T cells (Fig. 23A), VacA-treated primary T 
cells retain the capacity to secrete high levels of IL-2 (Fig. 23A).  The suppressive effect 
of VacA on Jurkat T cell proliferation has previously been attributed to suppression of 
IL-2 expression, occurring at the level of transcriptional regulation due to NFAT 
inhibition (34).  In contrast, our results provide evidence that VacA-mediated inhibition 
of primary human Th cell proliferation occurs at a later stage of T cell activation, wherein 
the immunosuppressive drugs cyclosporine A and FK-506 (NFAT-activation inhibitors) 
are no longer inhibitory (Fig. 24).  Specifically, we show for the first time that VacA 
impairs IL-2-driven cell-cycle progression in activated primary human Th cells (Fig. 25), 
resulting in an inhibition of IL-2-driven proliferation.  This effect of VacA resembles the 
actions of the immunosuppressive drugs rapamycin and sanglifehrin A (14, 114), two 
known inhibitors of IL-2-driven proliferation. 
We also show, based on analysis of single-point mutant toxins (Table 1), that the 
inhibitory effects of VacA on primary human Th cell proliferation and IL-2 secretion in 
Jurkat T cells are dependent on the integrity of the VacA N-terminal hydrophobic 
domain, which is required for formation of membrane channels (Fig. 22) (52, 100).  This 
provides strong evidence that VacA-mediated effects on T cell proliferation are 
dependent on the formation of membrane channels.  This conclusion is consistent with 
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data reported by Boncristiano et al, who showed that various VacA effects on Jurkat T 
cells could be blocked by NPPB, a non-specific chloride channel inhibitor (12).  One of 
the VacA mutant toxins in the current study, VacA-∆(6-27), potently blocked the effects 
of wild-type VacA on T cells (Fig. 27).  This dominant-negative mutant VacA protein 
interacts with wild-type toxin, resulting in the formation of non-functional mixed-
oligomeric structures (100).  Inhibition of wild-type VacA activity by a dominant 
negative mutant protein is consistent with a model in which the formation of oligomeric 
VacA structures, such as membrane channels, is required for VacA-induced effects on T 
cells.  We hypothesize that formation of anion-selective VacA membrane channels 
induces membrane-depolarization of T cells, and that this phenomenon is mechanistically 
important in the inhibition of IL-2-dependent T cell proliferation.  Consistent with this 
view, Boncristiano et al recently reported that VacA could block ionophore-stimulated 
influx of calcium into T cells (12).  Furthermore, a previous study demonstrated that 
activation of glycine-gated chloride channels induces membrane depolarization of T 
cells, resulting in a decreased open probability of plasma membrane calcium channels 
and in the inhibition of IL-2-dependent proliferation without affecting IL-2 secretion or 
NFAT activation (84).  
The current results, along with two recent studies, provide evidence that   VacA 
interferes with T cells proliferation by affecting multiple mechanisms.  VacA is capable 
of inhibiting T cell activation by blocking the activation of NFAT (12, 34), and we now 
show that VacA is also capable of inhibiting IL-2-driven proliferation of T cells.  In 
addition to these effects, VacA has been reported to interfere with T cell activation 
through a channel-independent mechanism that involves activation of intracellular 
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signaling through the mitogen-actived protein kinases MKK3/6 and p38 and the Rac-
specific nucleotide exchange factor, Vav (12).  Together, these findings suggest that the 
effects of VacA on the immune system are likely to be multi-factorial and more complex 
than initially thought.     
Gastric biopsies from H. pylori-infected individuals consistently demonstrate 
infiltration of immune cells including CD4+ T helper cells, and specific anti-H. pylori T 
cells have been detected in the gastric mucosa (2, 22, 41, 45).  Nevertheless, H. pylori is 
able to evade the immune response and establish persistent infection.  Experiments in 
mice indicate that the quality of the Th cell response is critically important for eradication 
of H. pylori and prevention of H. pylori-induced pathology (2, 45).  We propose that 
VacA might inhibit the clonal expansion and thus the acquisition of effector functions of 
infiltrating Th cells that have already been activated by H. pylori antigens.  This 
immunosuppressive activity of VacA is likely to play an important role in the process by 
which H. pylori evades the adaptive immune response.    
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CHAPTER V 
 
SUMMARY 
 
Conclusions  
H. pylori is the causative agent of most cases of duodenal ulcer disease and is 
considered a major risk factor for the development of gastric cancer.  Experimental and 
epidemiological studies suggest that the vacuolating cytotoxin (VacA) is an important 
virulence factor in H. pylori pathogenesis, and that VacA contributes to the development 
of stomach and duodenal ulcers.  Thus, functional and structural studies of VacA might 
lead to the development of VacA inhibitors that could be used to block VacA activities. 
Approximately sixteen years have passed since the production of an H. pylori 
vacuolating toxin was first described by Leunk et al (43). Since then, VacA has been the 
focus of research of many laboratories around the world.  In comparison with other 
bacterial toxins (e.g. cholera, diphtheria, and anthrax toxin), relatively little is known 
about how VacA exhibits many of its effects on mammalian cells.  Over the past decade, 
several lines of evidence have indicated that VacA proteins form large oligomeric 
structures of ~1,000 kDa in mass.  These VacA oligomers formed in solution have a 
flower-like structure and are composed of anywhere from 6 to 14 VacA monomers.  The 
central ring in this VacA flower-like structure has been hypothesized to represent the 
VacA membrane channel, a hypothesis supported by the visualization of similar flower-
like structures in cell membranes and the formation of VacA channels in planar lipid 
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bilayers.  Thus, VacA-VacA interactions play an important role in VacA cytotoxic 
activity. 
One major limitation in the VacA field has been the lack of recombinant over-
expression systems that allow the production of large amounts of VacA proteins.  Several 
groups have previously attempted to express recombinant VacA, but most of them have 
failed, or were able to produce only inactive recombinant proteins.  Currently, VacA is 
purified from H. pylori broth culture supernatant in small amounts, sufficient to do 
limited experiments, but insufficient for undertaking structure-function analysis of this 
toxin.  Today, the three dimensional structure of VacA is not known, and a comparison of 
the VacA amino acid sequence with proteins in the data base has not produced any 
insight into putative VacA domains.   
Prior to undertaking this thesis projects, two putative VacA domains had been 
described in the literature.  The mature secreted 88 kDa VacA can undergo limited 
proteolysis into 33- and 55-kDa fragments (p33 and p55 respectively), which might 
represent two VacA domains.  However, very little was known about the function of 
these two domains.  The main goal of this thesis was to characterize the role of p33 and 
p55 domains in the process of VacA oligomerization and intoxication of mammalian 
cells.  Together, this thesis describes the functional characterization of the p33 and p55 
VacA domains using a plethora of different approaches, in which each technique has 
provided insight into the importance of these domains for VacA assembly into oligomeric 
structures and cytotoxic activity.     
Chapter II of this thesis describes the use of a yeast two-hybrid system to study 
possible physical interactions between the p33 and p55 VacA domains.  It was 
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demonstrated that the p33 and p55 domains were able to form heterotypic complexes 
inside yeast cells.  The utility of the yeast two-hybrid system to study VacA-VacA 
interactions was further demonstrated by analyzing a collection of VacA mutant proteins.  
Analysis of these mutant proteins indicated a strong correlation between the capacity of 
p33 and p55 proteins to interact, the formation of oligomeric structures, and vacuolating 
activity of full-length VacA proteins harboring the same mutations.  In addition, analysis 
of a variety of p33 and p55 mutants and truncated proteins in the yeast two-hybrid system 
allowed for the mapping of putative minimal interaction domains in both the p33 and p55 
domains.  Additional data resulted from the generation and characterization of a VacA 
protein containing a FLAG-enterokinase tag (FLAG-vacA).  Characterization of the 
FLAG-VacA protein indicated that the p33 and p55 interactions occur within VacA 
oligomeric structures formed by the H. pylori VacA protein.  Collectively, these 
experiments provided strong evidence that the p33 and p55 domains of the VacA protein 
interact with each other and that these interactions play an important role in VacA 
oligomerization and vacuolating activity. 
Chapter III describes expression and functional characterization of the p33 and 
p55 VacA domains.  This is the first time that recombinant expression of active p33 and 
p55 VacA domains in E. coli has been described.  In addition, this chapter also describes 
the role of these domains in the process of VacA-mammalian cell interactions.  
Previously it was thought that the p55 domain was responsible for VacA binding to 
mammalian cells and that the p33 domain was responsible for membrane insertion and 
channel formation.  Studies using the recombinant p33 and p55 domains indicate that 
both of these domains are able to interact with host cell membranes.  Interestingly, it was 
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demonstrated that even though the p33 and p55 bound to cells independently, both of the 
domains were required for VacA internalization into host cells.  Furthermore, studies in 
which p33 and p55 were added sequentially to cells suggested that p55 binding, but not 
p33 binding, is critical for cell vacuolation.  One possibility is that p33 and p55 may bind 
to different receptors, and that only the receptor bound by p55 allows the toxin to be 
internalized by cells.  What is clear from these studies is that VacA might be able to bind 
to different molecules on the cell surface, but the process of VacA binding and 
internalization seems to required p55/cell interactions.  These results also provide some 
insight into the complexity of VacA-cell interactions, since based on these results, VacA 
is the first pore-forming toxin for which toxin activity can be reconstituted from two 
separate fragments.  This is interesting because it might suggest that VacA structure, as 
well as the mechanism of VacA membrane-insertion, might be different from what has 
been described for all the other pore-forming toxins.     
This thesis work extensively describes the importance of the p33 and p55 domains 
for the process of VacA intoxication of mammalian cells.  In addition, it also describes 
several novel tools for VacA research that will be useful for further investigation of VacA 
structure and function.  The yeast two-hybrid system is one of the first systems in which 
VacA-VacA interactions could be studied in a high-throughput assay.  This will allow the 
mapping of specific residues or regions important for p33/p55 interactions, which then 
can be validated by incorporating the mutations either in the H. pylori system or in the 
recombinant system.  Also, the recombinant expression of active p33 and p55 domains is 
a major step forward in our efforts to further understand VacA structure function 
relationships, since these fragments can be generated in larger amounts than the amount 
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of VacA currently generated in the H. pylori system.  Furthermore, purification of these 
domains might facilitate the crystallization and structural analysis of VacA, since several 
previous crystallization attempts using the full-length VacA toxin have failed. 
VacA is able to exhibit many different effects on mammalian cells.  One area of 
research that has become very popular recently is the characterization of VacA effects on 
immune cells.  In chapter IV, VacA effects on primary human CD4+ T cells were 
investigated.  From this study it is clear that VacA exhibits different effects on primary 
human T cells compared to transformed human T cell lines.  VacA inhibition of Jurkat T 
cell proliferation has been attributed to its potent inhibitory effect on IL-2 production 
(34).  IL-2 is required for primary T cells to proliferate in vitro and in vivo upon 
activation.  Interestingly, Jurkat T cells do not require IL-2 or TCR/CD28 activation for 
their proliferation in vitro.  Therefore, the significance of VacA effects on IL-2 
production in Jurkat T cells is somewhat controversial.  Similar to reports using Jurkat T 
cells, when primary human T cells are intoxicated with VacA, they are impaired in their 
ability to proliferate.  In contrast to Jurkat T cells, VacA has only minimal effects on IL-2 
secretion in these cells, an effect that appears to be biologically insignificant.  This 
finding is not surprising given that Jurkat T cells and primary human T cells have been 
shown to differ substantially in the transcriptional regulation of genes and the activation 
of multiple transcription factors upon activation (37, 60).  Further analysis of VacA-
mediated inhibition of primary human Th cell proliferation indicated that VacA inhibits 
primary human Th by impairing the IL-2-induced cell-cycle progression, resulting in an 
inhibition of IL-2-driven proliferation.  The precise biochemical mechanism by which 
VacA inhibits IL-2-driven signals is not known, but formation of membrane channels by 
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VacA seems to be required.  This observation is important, not only for the understanding 
of VacA-mediated effects on T cells, but little is known about the role of membrane 
channels in cell cycle progression and proliferation.  It might be possible to use VacA as 
a tool to further understand how an anion-selective membrane channel might control cell 
proliferation.  
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Future Directions 
 
Purification of the recombinant p33 and p55 VacA domains
One of the most important areas to emphasize in the future is the expression, 
purification, and further analysis of the p33 and p55 domains.  Currently the expression 
of these proteins has not been optimized to obtain the highest amount or the highest 
levels of functionally active protein, which might facilitate the purification process.  
VacA has a tendency to stick to everything, including purification resins.  In the case of 
the p33His and p55His VacA proteins, most of the protein remains is soluble when 
expressed at relatively low levels, but almost all the attempts to purify these protein by 
applying the soluble lysates to a nickel column have failed.  The reason for this result is 
not known, but it might be possible that the VacA proteins are associated with E. coli 
proteins or E. coli lipids, which in turn make the His-tag inaccessible.  In the future it 
might be worth trying different tags or different expression conditions that could support 
binding and elution of the recombinant proteins from the purification columns. 
 
Identification of the p33 and p55 receptors
Several putative VacA receptors have been described in the literature, but whether 
VacA has a specific receptor is controversial.  Interestingly, the work described in 
chapter III indicates that both the p33 and p55 VacA domains are able to interact with 
cell surfaces and that they interact with cells at higher levels when both p33 and p55 are 
present.  Thus, it would be interesting to investigate if these domains bind to different cell 
molecules when added individually compared to when added together.  In particular, 
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investigation of the role of lipid rafts seems really interesting.  Previously, lipid rafts have 
been shown to be required for VacA vacuolating cytotoxic activity (81), presumably due 
to their role in VacA binding and/or internalization.  Whether p33 and p55 localize to 
lipid rafts when added individually or when added together to cells is not currently 
known.  These studies might provide insight into cell surface molecules required for 
VacA internalization, and might help to clarify the specific role of lipid rafts in the VacA 
intoxication process. 
 
Intracellular localization of the p33 and p55 VacA domains 
VacA has been previously shown to localize within cells in late endocytic 
compartments as well as mitochondria, but whether both p33 and p55 VacA domains are 
required for VacA targeting to specific intracellular organelles is not currently known.  
The feasibility to detect the p33 and p55 domains inside cells by immunofluorescence 
might allow us to investigate further the trafficking of these two domains to different cell 
organelles.  It could be possible that the p33 and p55 domains target several different 
sites depending on whether the domains are assembled as an 88 kDa complex or as single 
p33 and p55 molecules. 
 
Cellular target proteins of the p33 and p55 VacA domains
Two previous studies have identified two putative VacA intracellular-interacting 
proteins.  First, screening of a HeLa cell library with p55 revealed that this VacA domain 
interacts with a novel protein of 54 kDa (VacA interacting protein 54 kDa; VIP54).  
VIP54 distribution in cells shows a fibrous pattern typical of intermediate filaments, to 
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the distribution of vimentin, but the physiological significance of the p55/VIP54 
interaction is not clear.  Second, screening of a human gastric mucosa cDNA library with 
different VacA fragments indicated that a VacA fragment containing mainly the C-
terminus of p33 domain interacts with RACK1, a receptor for activated protein kinase C 
(PKC), but again the functional significance of this interaction is unknown.   
One possible problem with the previous yeast two hybrid analyses is that there is 
no evidence that the VacA fragments used in these previous studies are capable of 
exhibiting any activity.  Therefore, it could be possible that by using VacA bait proteins 
known to exhibit activity when expressed within yeast cells, different results might be 
obtained, which in turn, might provide insight into putative VacA cellular targets.  
Chapter III described the generation of p33 and p55 yeast two hybrid vectors that express 
functional p33 and p55 proteins, which could form p33/p55 complexes.  These proteins 
could be used to screen cDNA libraries of mammalian cells.  Since HeLa and gastric cell 
libraries have already been screened, it might be interesting to screen libraries from 
immune cells, since VacA has been shown to affect several immunologic processes.  To 
this end, a mouse splenocyte cDNA library compatible with the yeast two-hybrid system 
used in chapter III has been obtained and will be screened against the functional p33 and 
p55 domains used in chapter three.  This screen might provide insight into putative cell 
proteins that facilitate VacA effects on mammalian cells, in particular, immune cells. 
 
Biochemical mechanism of VacA-mediated inhibition of primary human T 
cell proliferation 
 
As described in chapter IV, VacA inhibits primary human T cells by impairing the 
IL-2 signaling pathway, but the precise molecular mechanism used by VacA to achieve 
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this end is not known.  The IL-2 signaling pathway starts by the upregulation of the 
expression of IL-2 and the high affinity IL-2 receptor alpha (CD25), producing an 
autocrine system.  Previously we have shown VacA does not affect the secretion of IL-2 
or the surface expression of CD25 in primary human CD4+ T cells (Chapter IV).  Once 
the IL-2 binds to the trimeric IL-2 receptor (i.e. IL-2 receptor is composed of α, β, and γ 
chains) a complex signaling cascade is initiated resulting in two major outcomes, cell 
survival and cell proliferation.  Whether VacA affects the oligomerization of the IL-2 
receptor or signals triggered by the IL-2/IL-2R complex by inserting into T cell 
membranes has not been analyzed yet.  Preliminary studies indicate that VacA does not 
affect the formation of the IL-2R trimeric complex nor the initial membrane proximal 
signals.  This preliminary conclusion arises from studies of the activation of downstream 
molecules upon IL-2 stimulation.  Primary human T cells intoxicated with either VacA or 
control buffer were each able to activate a key signaling molecule, signal transducer and 
activator of transcription 5 (STAT-5) upon IL-2 stimulation (i.e. STAT-5 is 
phosphorylated by the Janus kinase-3).  Activation of STAT-5 upon IL-2 stimulation 
suggests that the membrane proximal signals triggered by the IL-2/IL-2 receptor complex 
are intact upon VacA intoxication.  
In order to gain insight into the signaling pathways blocked by VacA in T cells, a 
global protein expression analysis might be useful.  For these experiments, primary 
human T cells can be intoxicated with VacA and total cellular proteins isolated.  To 
permit a rapid and efficient assessment of effects of VacA on protein expression, lysates 
from VacA-treated cells and control cells can then be used for a high-throughput 
immunoblot analysis with a panel of ~1000 antibodies (PowerBlot analysis; Becton-
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Dickenson Biosciences Pharmingen).  This panel of antibodies includes a large number 
of antibodies against molecules involved in signaling and cell cycle regulation, as well as 
other antibodies of interest.  These results might help to identify specific signaling 
pathways that are altered in response to VacA.  In addition, transcriptional analyses of 
intoxicated cells might be useful. 
 
VacA as a tool to understand signals involved in HIV infection of primary 
human T cells 
 
Human CD4+ T cells are the major target of HIV infection and replication in vivo.  
It has been well established that HIV infection of primary human T cells requires T cell 
activation signals, such as from the T cell receptor (TCR) and the co-stimulatory receptor 
CD28 (64).  How T cell activation signals promote susceptibility of resting human T cells 
to HIV infection remains poorly understood, but the thresholds of T cell activation and 
IL-2 signals are critical for HIV to establish productive infection.  Chapter IV described 
studies indicating that activation-induced proliferation of T cells can be inhibited by 
intoxication of these cells with VacA.  VacA inhibits activation-induced proliferation of 
T cells without causing any detectable alterations in cell viability, and seems to affect the 
IL-2/IL-2 receptor proliferation signals.  Therefore, VacA might serve as a new tool for 
further dissecting the T cell signaling pathways that are required for HIV infection of T 
cells.  In fact, our preliminary studies suggest that VacA is able to inhibit HIV infection 
of T cells.  Thus, investigation of the mechanism by which VacA inhibits HIV infection 
of T cells are likely to provide important new insights into our understanding of the T cell 
activation signals that are required for HIV infection, and may also reveal a very 
interesting pathogen-host-pathogen interaction.  
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Last remarks 
 
How virulence factors produced by pathogens affect cellular processes is an 
important question in the microbiology field.  One of the most interesting groups of 
virulence factors are bacterial toxins.  In the case of H. pylori, the only known secreted 
toxin is the vacuolating cytotoxin (VacA).  In comparison to other pore-forming toxins, 
VacA exhibits several unique properties.  Most pore-forming toxins are extremely toxic 
toward their target cells, whereas VacA either does not cause cell death or induces 
apoptosis via a slow process.  Another unique future of VacA is that it is internalized into 
mammalian cells, a phenomenon that is not observed with most other pore-forming 
toxins.  Furthermore, VacA seems to exhibit a wide variety of effects on different 
mammalian cell types.  All these observations suggest that VacA is a multifunctional 
toxin with unique properties. The work presented in this thesis provides insight into the 
structure-function complexity of this toxin.   
One of the most interesting VacA activities is its immunosuppressive effect on 
human T cells.  This VacA-mediated effect might play a role in the ability of H. pylori to 
establish a persistent infection that can last the life span of an individual.  Understanding 
the mechanism by which VacA affects T cells might provide new insights into T cell 
signaling pathways.  Moreover, modulation of T cells by VacA or related molecules 
might be clinically useful to suppress inflammatory diseases.   
In summary, understanding of VacA mechanism of actions will not only be useful 
to understand the role of this toxin in H. pylori pathogenesis but it could also provide 
important information at the cell biology level that can then be used to address other 
important  biological problems.  
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